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INTRODUCTION 
 
Poison is any substance which causes bodily harm or risk to life by means of exposure 
through inhalation, ingestion or contact. 
 Pesticide is a type of poison which has been used by humans for deliberate self harm. 
Pesticide ingestion has been identified by WHO as the commonest cause of deliberate 
self harm all over the world.(1)  
Organophosphorus poisoning is the commonest cause of deliberate self harm in India. 
They act by inhibition of acetyl cholinesterase. Inhibition of Acetyl cholinesterase causes 
accumulation of excessive levels of the enzymes leading to characteristic signs and 
symptoms (2). RBC cholinesterase and butyl cholinesterase (pseudo cholinesterase) are 
commonly used for determination of organophosphorus and carbamate poisoning. 
However, only RBC cholinesterase has been proposed to have good correlation with the 
neuromuscular weakness caused by organophosphorus poison (3).RBC correlation has 
been shown to have correlation with severity of poisoning too (4). 
 
 Butyl cholinesterase and not RBC cholinesterase is still routinely used for confirmation 
of poisoning but it cannot be used to ascertain severity or prognosis. Red blood cell 
esterase detecting mobile machines have been used in Germany in past for settings other 
than deliberate self harm like military purposes and agriculture exposures. In different 
validation studies was proven that this  machines could be used as a good guide for 
12 
 
estimation of organophosphorus poisoning(5). We in this study used bed side estimation 
of RBC cholinesterase at admission to assess the correlation with severity of poisoning, 
atropine requirements and prognosis in organophosphorus and carbamate poisoning. We 
also looked into different factors that determine the atropine requirements and the rates of 
ventilation, mortality, rates of intermediate syndrome and duration of hospital stay in this 
cohort of patients.  
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AIM: 
 
 
  The dose and determinants of atropine requirements and outcomes in acute   
organophosphate and carbamate poisoning 
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OBJECTIVES: 
 
1) To assess the correlation between  RBC cholinesterase at admission and 
severity and requirements of atropine for treatment 
 
2)  To assess the dosing and various factors which determine the atropine 
requirement in organophosphorus and carbamate poisoning 
 
3) To assess rates of ventilation, mortality, rates of intermediate syndrome and 
duration of hospital stay in the same patients  
 
4)  Assess for possible atropine toxicities in form of delirium and                 
hallucinations and requirement of physical and chemical restrains by using   
Confusion assessment method.  
 
5) The differences in atropine requirements for initial atropinisation and outcomes in 
different severity of op poisoning using Peradeniya organophosphorus poisoning (POP) 
scale  
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LITERATURE REVIEW  
 
SUICIDES IN WORLD 
 
Deliberate self harm or suicide has long been recognized as a social hazard. In the year of 
2003, WHO in its world health report pointed out self inflicted harm as the 6
th
 
commonest cause of mortality in the 15-59 years age group ranking above infectious 
causes like pneumonias and other important causes like chronic liver disease and 
COPD(6). According to WHO almost a million people lose their lives to suicide and a 
global mortality rate of 16 people per lakh which translates to a death due to deliberate 
self harm every 40 seconds and almost 20 times this number attempt suicide which leads 
to a suicide attempt every 3 seconds. In 1998, suicide was estimated to cause 1.8 percent 
of global burden of diseases and it is expected to go up to as high as 2.4 percent by 2020 
(7). Deliberate self harm using poisons is a global health hazard. WHO has recognized 
pesticide poisoning as the largest group among the causes of deliberate self harm. It has 
also decided on a response operation by the launch of a global pesticide and health 
initiative(8).  
 
SUICIDES IN INDIA  
 
India ranks 43rd in the world according to rates of suicides all over the world with a 
published rate of 10.6 per lakh population according to the WHO document published in 
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2009.  The suicide rates in India have been rising. It was estimated at 6.3 per lakh in the 
year 1978 which rose to 8.9 per lakh by 1990 and the most recent reports submitted by 
National Crime Records Bureau (NCRB) from 2010 show the rate to be 11.4 percent per 
1 lakh (7).  
The million death study has showed that about 3.7 percent of all deaths in India are due to 
deliberate self harm. This number leads us to about 187000 deaths due to suicides per 
years which is much more than the WHO estimations. In this study which was done to 
assess mortality rate and its leading causes, it was found that 2684 deaths out of 95335 
deaths that occurred among the study group were due to suicides. It also concluded that 
the group with highest suicide related deaths was 15-29 years age group (13 percent). It 
also showed that south India had a higher rate of suicide related deaths as compared to 
rest of India (5 percent) (9).  
Tamil Nadu was found to have the highest numbers of suicide related deaths in 2012 and 
later 2
nd
  highest in 2014 contributing 12% of such deaths (10).  
 
 
SUICIDE DUE TO POISONING IN INDIA 
 
According to a recently published systematic review and meta analysis published on 
suicides in India, poisoning was 2
nd
 most commonest method of suicide (16-49 percent) 
second only to hanging (11).  
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According to medical reports on certification of cause of deaths 2013, poisoning, injury 
and other external causes as 5
th
 leading cause of death contributing about 1.5 percent of 
all medically certified deaths (12).  
This might be a gross underestimation and we might be looking only at the tip of an 
iceberg since only 20 percent of deaths in India are reported.  
 
 
WORLD PESTICIDE POISONING EPIDEMIOLOGY  
 
On the basis of studies done in Srilanka by Jeyaratnam (1984) it was estimated that about 
220000 deaths happen due to pesticide poisoning per year and a majority of which is with 
intent of deliberate self harm. More recent extrapolation from this data has suggested that 
there are about 300000 deaths every year due to pesticide ingestion in Asia alone. The 
WHO has now announced pesticide ingestion as the commonest cause for suicidal deaths.  
It is a very cheap and easily over the counter available method of deliberate self harm and 
thus is the commonest. Its estimated that about 30 percent of all suicidal deaths are due to 
pesticide consumption (13).   
Pesticide poisoning is a major health issue in the Asian countries like India, Sri Lanka, 
Vietnam and China. They account for 60% of suicides which occur mostly in rural areas 
of south East Asian countries.  
18 
 
OP POISONING IN INDIAN SCENARIO 
 
Acute organophosphorus poisoning is the commonest cause of poisonings in India. 
According to a study, India has a production of 145 different pesticides. OP poisons 
which are cholinesterase inhibitor (35.1%) were the commonest class of poisons 
consumed for self harm. A seasonal variation in anti cholinesterase poisoning was 
observed which was seen most in months from July to September (14).  
WHO INITIATIVE TO REDUCE POISONINGS  
 
WHO has taken multiple steps to reduce the incidence of deliberate poisoning. Some of 
them are as follows 
(1) Regulation of the pesticide policies,  
(2)  Mental health and medical care improvement 
 (3) To develop Surveillance and poisoning monitoring facilities  
 (4) Safe handling training 
 (5) Interventions by Community for safe storage of pesticides. 
WHO has advised on legislatures for the ban of highly toxic pesticides (WHO class 1 and 
2) and it has led to reduction in mortality in countries like Srilanka and Jordan.  
However, In India WHO class 1 poisons are still available freely.  
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OP POISONING EPIDEMIOLOGY IN CMC  
 
According to a retrospective study published by Dr Peter J V et al 422 charts of patients 
with organophosphorus poisoning could be retrieved from a time period of 6 years out of 
which 396 patients met all criteria for study.  
The mean age of the patients was 31.4 +/- 12.7 years with a male to female ratio of 2.6:1. 
The Median admission level of pseudo cholinesterase (interquartile range) was 317 (222–
635) U/L. 33 patients (8.3%) of patients in this study had received oximes prior to being 
referred to CMC. Dimethyl compounds were ingested by 141 patients, while 108 had 
consumed diethyl compounds, S-alkyl organophosphate by 2. In 145 of the patients there 
was classical toxidrome and low cholinesterase levels however, the compound could not 
be recognized.  
260 patients (65.7%) needed ventilation with a median duration of ventilation of 7.5 (IQR 
3–12) days. The Overall mortality during the study period was 13.1% (15). This is said to 
have decreased to less than 5 percent currently.  
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HISTORY AND GENERAL STRUCTURE OF ORGANOPHOSPHORUS 
COMPOUNDS  
 
The organophosphorus compounds were first synthesized in 19
th
 century and they came 
into popular use by 1930s. Gerhard Schrad, a German chemist synthesized multiple 
compounds of which parathion is the most famous one. When the world war started the 
more toxic nerve gases were developed like sarin and soman. OP compounds sprung back 
into the picture in 1970s again when organo chlorine compounds like DDT were 
prohibited in the fear of their long persistence in the environment.  
 
Organophosphorus compounds are phosphoric acid esters and derivatives from it. The 
general molecular framework of OP compound comprises of a phosphorus atom in the 
centre with a thiophosphoric or phosphoric bond. X stands for the group which leaves 
and is replaced via a nucleophilic substitution by oxygen from serine in the acetyl 
cholinesterase active site. This leaving group(x) decides the affinity of the inhibitor. The 
easier the group X   leaves, the higher is the affinity of the compound to bind and inhibit 
ACHE (16). 
 
 Figure – 1  Structure of organophosphorus compound 
 
(17) 
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Studies in the past have shown that the severity of poisoning depends on the type of OP 
compound. Dimethyl compounds have been found to have a worse outcome and longer 
requirement of treatment as compared to diethyl ones (15).  This may be due to the 
longer half life and higher capacity to regenerate ACHE with diethyl compounds.(1/2 life 
Dimethyl – 3 hours, Diethyl – 30hours)(18) 
  
CLASSIFICATION OF OP AND CARBAMATE POISONS 
 
WHO came up with a revised classification in 2009 for poisons according to their 
hazardous potentials measured by the LD 50 in rats. The organophosphorus compounds 
and carbamate can also be classified on this basis.  
 
Table 1 : WHO classification of pesticides - taken from WHO recommended classification 
of pesticides by hazard (19) 
Following is a table of organophosphorus compound with their WHO classes according 
to the WHO updated classification in 2009. 
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WHO class of compounds  Compound names 
Class I a Methyl Parathion, Phosphamidon, Phorate 
Class I b Monocrotophos, Triazophos, Dichlorvos 
Class II  Quinalphos, Chlorpyrifos, Dimethoate, 
Fenthion, Profenofos, Phenthoate, Ethion 
Class III Malathion, Acephate  
Table 2 : WHO classification of OP 
Classification of organophosphorus compounds on basis of structure of alkyl groups 
attached: 
 
1. Dimethyl compounds – Methyl Parathion, Monochrotophos, Fenthion and Dimethoate 
2. Diethyl compounds -   Quinalphos, parathion, Chlorpyrifos  
3. S- Alkyl group – Profenophos  
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STRUCTURE AND FUNCTION OF ACETYL 
CHOLINE ESTERASE 
 
Acetyl cholinesterase is a hydrolases that is specific to hydrolysis of the neurotransmitter 
acetyl choline. The oligomeric forms from torpedo and electrophorus have been used as a 
source of acetyl cholinesterase for studies.  Kinetic studies on this enzyme have shown 
that there are two subsites- known as the esteratic and anionic subsites. The esteratic 
subsite supposedly resembles the catalytic site of other serine hydrolases. The Anionic 
subsite binds with the charged quaternary group of choline.  
In additional to these two subsites in catalytic center, acetyl cholinesterase (ACHE) is 
supposed to have another peripheral anionic site. This was proven by Taylor and Lappi. 
This peripheral anionic site is supposed to be the cause of substrate inhibition 
characteristic of ACHE (20).  
Choline of the acetyl choline usually binds to the anionic subsite while acetyl group is at 
the esteratic site where the ester bond is hydrolysed and this leads to acetylated ACHE 
and choline. Acetylated ACHE later reacts with a molecule of water to form acetic acid 
and free enzyme. 
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Figure 2- Representation of structure of ACHE (20) 
   ES- Esteratic subsite, AS- anionic subsite PAS- Peripheral anionic subsite  
 
Organophosphates inhibit ACHE by phosphorylating the serine hydroxyl moiety at the 
active site in the same way as acetylation of ACHE happens. In contrast to the acetylated 
ACHE which is unstable and easily breaks down to release acetate and choline, the 
phosphorylated enzyme is stable and prevents the regeneration the enzyme. Thus the 
ACHE bound to organophosphates are unable to recycle acetylcholine and this excessive 
acetyl choline at the post synaptic membrane causes the symptoms(21) . Phosphorylated 
enzymes can then undergo a dealkylation reaction of the organophosphate moiety which 
renders the phosphorylated ACHE aged and it cannot be regenerated even with oximes.  
 
The organophosphates have high affinity for ACHE. They also inhibit hydrolases, 
examples of which are butyl cholinesterase also called the pseudo cholinesterase and 
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RBC cholinesterase. However it has been proven in studies that butyl cholinesterase 
inhibition doesn’t correlate to clinical severity. However, it is used to detect the 
poisoning (18) 
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MECHANISM OF TOXICITY OF ORGANOPHOSPHATES 
   
These compounds inhibit the synaptic enzyme acetyl cholinesterase (AChE) which 
breaks down acetylcholine leading to accumulation of acetylcholine at the synapses and 
overstimulation of muscarinic and nicotinic receptors of the central and autonomic 
nervous system and neuromuscular junction. AChE is an esterase enzyme that has two 
binding sites, namely the anionic and esteratic sites. OP compounds covalently react with 
the serine moiety in the estaratic site producing a serine-phosphoester bond due to this 
nucleophilic attack. This inactivates the enzyme preventing (22).Nerve agents are 
organophosphate compounds similar to those used as pesticides but with much higher 
toxicity. They all block the activity of the enzyme acetylcholine esterase. Victims are 
intoxicated by absorption of the toxin via exposed skin or, more commonly, via 
inhalation of the poisonous gas. The resultant clinical picture is of hyperstimulation of 
both the nicotinic and muscarinic cholinergic system, which, if not promptly treated, 
leads to severe muscle paralysis, cardiac brady-asystole, hypersecretion from secretory 
glands, respiratory failure, seizures, coma and death. If antidotal drugs are promptly 
administered, the clinical severity of the poisoning is attenuated or complete abortion of 
symptoms is obtained. The main therapeutic strategies include atropine and oximes that 
counteract the nerve-agent-induced muscarinic and nicotinic cholinergic symptoms, 
respectively. Anticonvulsants and sedatives are used to treat central nervous system 
acetylcholine esterase disarray. This review summarizes the biochemistry and 
pathophysiology of anticholinesterase poisoning, the relevant clinical manifestations and 
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the currently available therapeutic). Acetylcholine a neurotransmitter found in the 
neuromuscular junction, pre-ganglionic autonomic nerves as well as the post-ganglionic 
parasympathetic nerves. This is similar to butyrylcholinesterase which is present in 
plasma. The acetylcholine accumulation leads to generalised, prolonged central and 
peripheral post-synaptic stimulation. Nicotinic cholinergic receptor activation results in 
involuntary contraction of skeletal muscles manifested as fasciculations and complete 
depolarisation block which in turn causes flaccid paralysis. Muscarinic receptor 
activation activates the secretory glands resulting in the commonly described SLUDGE 
symptoms of organophosphorus poisoning which is composed of ‗Salivation, 
Lacrimation, Urination, Diaphoresis, Gastrointestinal upset and Emesis‘. Other 
muscarinic effects include bronchorrhoea, bronchoconstriction and miosis along with 
bradycardia. The central nervous system effects of the accumulated acetylcholine include 
disorientation, anxiety and seizures succeeded by loss of consciousness with respiratory 
arrest. Death may result due to cardiorespiratory arrest or due to prolonged seizures, 
especially in the nerve agents such as sabin and soman. The severity of these clinical 
manifestations depend on several factors including dose ingested, onset of action of the 
compound, rate of absorption and stability of the formulation. The oxons which do not 
require conversion to active form will have faster action but for the thions, onset of 
toxicity will vary depending on the rate of their activation. For example, parathion which 
gets activated rapidly will act faster than dimethoate which is a slow inhibitor of AChE as 
its conversion to omethoate, the oxon form, is slower. 
 
  
 
STRUCTURE OF CARBAMATE 
 
Figure 3: structure of carbamate poisons 
Carbamates are related to carbamic acid. 
They have a structure which is completely different from that of organophosphates. 
However, they act on the same enzymes and cause similar presentation. These 
compounds are transient cholinesterase inhibitors and classically act for less than 48 
hours. They have similar effects of cholinergic excess as with organophosphates and can 
even cause mortality. They do not however cause intermediate syndrome and other 
delayed complications.  
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CLINICAL FEATURES OF ORGANOPHORUS POISONS  
 
The different clinical features of organophosphorus poisoning can be presented classified 
as on basis of time duration, receptor involved, organ system involved etc.  
 
Clinical syndromes on basis of the time duration are following (23): 
1. Acute cholinergic crises (up to 24 hours) - weakness, cramps, fasciculation, salivation 
lacrimation, urination, defecation, vomiting, bradycardia, hypotension, miosis, 
convulsions, anxiety and respiratory depression 
2. Delayed (from 24 hours to 2 weeks) – intermediate syndrome, cholinergic symptoms, 
coma and extra pyramidal features.  
3. Late (beyond 2 weeks) – peripheral neuropathy  
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ACUTE CHOLINERGIC CRISES  
 
In the acute phase all receptors ie muscarinic, nicotinic and central receptor affects are 
seen. Acute muscarinic effects include bronchorrhea, salivation, urination and defecation. 
Acute muscarinic effects on the heart like hypotension and bradycardia can be serious 
threat to life. 
 
Nicotinic receptor effect leads to weakness of muscles, fasiculations which contributes to 
worsening dyspnoea. Nicotinic receptors are also present at autonomic ganglion which 
can lead to tachycardia, hypertension, sweating and mydriasis, although these effects are 
not very common.  
 
Central effects lead to agitation, confusion and occasionally seizures which along with 
muscarinic effects can lead to worsening dyspnoea, airway compromise and risk of death 
(23).  
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Table 3: OP effects on basis of receptors  
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INTERMEDIATE SYNDROME  
 
Wadia et al in 1974 described neurological manifestations in OP poisoning. They 
described that 26 percent of the cohort had a paralysis which they subdivided into type 1 
and type 2 groups.  Type 1 group was the ones who had low sensorium and had bilateral 
pyramidal signs and they responded to atropine. They described Type 2 group as the ones 
who developed weakness later while already on atropine infusion. These patients had 
areflexia, proximal muscle weakness and cranial nerve palsies. They were not responsive 
to atropine. Their electromyography showed type 2 paralysis and some of them had a 
classical myasthenia decremented response with repeated stimulation. This group of type 
2 paralysis patient did worse that type 1. They needed more invasive ventilation and had 
more deaths (24).   
The term ‘Intermediate syndrome’ was first used by Senanayake et al in 1987 when they 
noticed a group of patients had proximal limb muscles weakness, respiratory distress, 
neck flexor weakness and motor cranial neuropathies. This group developed these 
symptoms from 24-96 hours after the ingestion of poison. This followed a well defined 
cholinergic phase and was much before the late phase of peripheral neuropathy which 
happened after 2 weeks. This weakness persisted up to 18 days in this study (25). 
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The EMG in these patients with intermediate syndrome showed fade response on 
repeated stimulation but did not show the same on low frequency stimulation and there 
was no post tetanic facilitation suggestive of a post synaptic pathology.  
The compounds found to be associated with intermediate syndrome were Fenthion, 
Monocrotophos, Dimethoate and methamidophos (25) 
According to a retrospective study done in kasturba medical college, manipal 45 out of 
153 cases of organophosphorus poisoning that were admitted developed intermediate 
syndrome. Thus the incidence of intermediate syndrome was 29.4 percent. Methyl 
parathion was the commonest compound associated with it and mortality rate in those 
with intermediate syndrome was 22.3 percent (26).  
In an article published from our institution, the incidence of intermediate syndrome 
varied between Dimethyl (58 percent) and diethyl group (26 percent) with odds ratio of 
2.84 , 95% CI 1.38- 5.86 P=0.004 (15).  
The mechanism of intermediate syndrome has always been a point of controversy. 
According to a study done in our own institution, there was a high incidence of 
intermediate syndrome in patients who were severely poisoned.  BCHE and ACHE were 
persistently inhibited and was found to be associated with the severity of intermediate 
syndrome suggestive of the fact that ACHE inhibition may be the underlying mechanism 
of both cholinergic crises and intermediate syndrome. However, ACHE levels didn’t 
recover along with improvement of power after intermediate syndrome suggestive of 
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possibility of additional mechanisms. This additional mechanism may be oxidative 
damage of the muscle membranes by free radicals (27).  
 
DELAYED ORGANOPHOSPHORUS RELATED ENCEPHALOPATHY (DOPE)  
 
It is a relatively newly described clinical entity which sets in after 4-7 days of admission 
and is associated with features mimicking brain death. Patients have a sudden drop in 
sensorium to 2T with no clinically demonstrable brainstem reflexes or cortical activity, 
miosed pupils with a normal CT and CSF analysis. EEG shows bihemispheric slow wave 
disturbances. These patients improved with supportive therapy in ICU with ventilation in 
a mean duration of 8 days (28).  
In a review article by Dr Peter JV et al, the author describes DOPE as ‘CNS 
intermediate’. In this article he hypothesized that the delay in onset of encephalopathy 
was probably due to the lipid soluble OP compounds had slow and delayed release with 
saturation of CNS receptors in time instead of immediate symptoms. Low pseudo 
cholinesterase was recorded along with some cases needing higher dose of atropine to 
maintain heart rate during the period supporting the above mentioned hypothesis (23). 
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LATE ONSET SYMPTOMS 
  
The Organophosphorus induced delayed polyneuropathy (OPIDP) is classically described 
to start after 2-4 weeks and the recovery is usually delayed but complete. 
 The molecular target for this is neuropathy targeted esterase.  
The symptoms at presentation are usually paresthesias, cramping type pain in distal 
extremities. 
 Nerve conduction studies show reduced CMAP (compound motor action potential), 
prolonged distal latencies and mildly reduced conduction velocities. Nerve biopsy done 
on such patients show axonal degeneration and secondary demyelination changes (23).  
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ASSESMENT OF SEVERITY OF POISONING 
In 1993, senanayake published a severity scale using 5 clinical cardinal symptoms and 
numbered them from 0-11 to grade the severity of OP poisoning. This came to be known 
as the Peradeniya organophosphorus scale and was subsequently validated (29) . 
Serial 
no. 
Parameter  Score  
1. Miosis   
 Pupil size > or = 2  0 
 Pupil size < 2  1 
 Pin point pupil 2 
2 Fasciculation  
 None  0 
 Present but not generalized or continuous 1 
 Generalized and continuous with central 
cyanosis  
2 
3 Respiration  
 Respiratory rate < or = 20 0 
 Respiratory rate > 20 1 
 Respiratory rate > 20 with central cyanosis  2 
4 Bradycardia   
 Heart rate > 60/min  0 
 Heart rate 40-60/min  1 
 Heart rate < or = 40 /min 2 
5 Level of consciousness   
 Conscious and rational  0 
 Impaired response to verbal command 1 
 No response to verbal command  2 
 Seizures present  Add 1  
 
Table 4: Peradeniya organophosphorus poisoning (POP) scale  
Total score calculated from this was then used to grade the severity. 
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TOTAL SCORE (out of 11) 
< 4 – Mild          4-7 – Moderate     8-11 - Severe  
 
 
DIAGNOSIS OF ORGANOPHOSPHORUS POISONING  
Organophosphorus poisoning in developing countries like ours is diagnosed on the basis 
of specific toxidrome of cholinergic crises. The major differential for organophosphorus 
poisoning is carbamate poisoning which is initially cannot be differentiated.  
The Acetyl cholinesterase enzyme has been described to have three isoforms formed by 
alternative splicing of the pre m-RNA. The specific biological role of each of these 
isoforms is different and they thus have different concentration in different tissues of the 
body although they have the same catalytic properties. The ACHE-S or the synaptic form 
is the one present in synaptic vesicles is found in brain and neuromuscular junctions. The 
ACHE- E isoforms or so called RBC cholinesterase is bound to the surface of RBCs. 
Although it is the ACHE-S levels whose inhibition is clinically relevant in central or 
peripheral nervous system, it is impractical to collect ACHE – S for evaluation from 
synapses, ACHE- E can be used as a surrogate marker.  Butyl cholinesterase also known 
as pseudo cholinesterase levels are used in most centers for confirmation of the diagnosis 
of organophosphorus poisoning due to its ease of estimation from plasma although its 
action is different from that of ACHE(18).  
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Butyl Cholinesterase  
Butyl Cholinesterase can be used for the diagnosis of organophosphorus and carbamate 
poisoning. However, it cannot be used for assessing the severity and follow up of the 
patients. Many OP compounds are most potent inhibitors of butyl cholinesterase as 
compared to ACHE and thus its levels may be much lower than expected in a clinical 
setting (18).  
Butyl cholinesterase is produced in the liver and it rises by 7 % per day after 
organophosphate is eliminated from the body (18).  
Butyl cholinesterase has a wide range of normal level (3000-7000 u/l). Hence with 
minimal inhibitions, the value might still be in normal range. It is also affected by many 
other conditions like pregnancy, liver disease and drugs.  
There is a large variability between different commercial kits and this can make the 
comparability between done in different studies difficult. This method is also dependant 
over the amount of substrate butyl choline and the temperature of the plasma. The butyl 
cholinesterase level increases by 4 % with each 1centigrade rise in temperature (18).  
 
RBC cholinesterase  
This cholinesterase is attached to the surface of red blood cells and is considered to be a 
good marker of synaptic ACHE inhibition and poisoning severity. This enzyme is 
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measured in whole blood in which butyl cholinesterase has been inactivated. RBC 
cholinesterase level in plasma and serum is very low.  
Once this enzyme has aged, it recovers only by the formation of new RBCs. This 
recovery occurs at a rate of 1 % per day and is slow. The rate of synaptic ACHE is not 
known and thus RBC ACHE can’t be used to monitor of recovery from poisoning. RBC 
cholinesterase levels are also affected by the PH, level of substrate and oximes in blood, 
temperature, time to cooling and dilution (18).  
 
 Thiermann et al in a study have reported correlation between RBC ACHE and 
neuromuscular weakness. They reported that a RBC ACHE activity less than 10 % 
correlated with severe neuromuscular transmission inhibition this was further confirmed 
with the electromyography studies showing decremental phenomenon. Moderate 
inhibition of RBC ACHE activity (10-30%) was associated with impaired neuromuscular 
transmission and a level > 30 percent was associated with a normal response. This study 
provides the basis of measuring an admission RBC cholinesterase to determine the 
severity of poisoning (30).  
 
DIFFERENT METHODS OF ACHE MEASUREMENT 
LABORATORY METHODS  
1. Delta pH method of Michel (1949) 
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2. Radioactive ACHE method of Johnson and Russell (1975) 
3. Kinetic assays by Ellman et al (1961) 
 
The kinetic assays by Ellman are the commonest ones used to assess BCHE and ACHE 
activity.  Thiocholine is used as substrate for this method and measures its hydrolysis 
caused by ACHE or butyl cholinesterase to give acetate or butyrate and thiocholine. The 
thiocholine binds to 5,5’ Dithiobis 2- nitro benzoic acid producing an acidic anion called 
5-thio-thionitrobenzoic acid which is yellow in color and is picked up by the 
spectrophometer to give values according to the intensity of the color produced  (31). 
There have been studies to compare the different lab methods to measure ACHE and it 
was found that Ellman method was the most sensitive method with an ability to pick up 
even mild inhibition of ACHE thus detective of early warning signs (31).   
FIELD TESTING KITS 
There are two field testing kit system available for use, there might be many variations of 
these two with minor changes available for use. 
The field testing kits are- 
1) Test-mate ChE system  
2) Lovibond Cholinesterase AF 267 test kit  
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The Test-mate system is a field testing kit which has been approved by the United states 
FDA. EQM research Inc is the manufacturer of this system. This system needs 10 micro 
liter of blood and the test has rapid turnover of lesser than 4 minutes. This Field kit works 
on Ellman method and can be used to measure ACHE or butyl cholinesterase on basis of 
which assay kit and CHE inhibiting agent is used. It measures Hemoglobin and has an 
internal reagent blank to improve photometric measurement. A compact photometric 
analyzer is used to measure the enzyme activity. The results are normalized to 
temperature of 25 C and to the hemoglobin level for ACHE and are expressed as u/ml 
Test-mate system has been compared other methods from lab like Ellman and Delta pH  
Methods <Wilson, 2006>. There was a good agreement between Test- mate and other methods. 
.  
The Lovibond cholinesterase 267 AF method is marketed as a rapid test for exposure to 
organophosphorus pesticides. This method is relatively crude and uses color comparator 
instead of photometric analyzer. This cannot be used for study or clinical purposes.  
 
Cholinesterase Rapid Test IVD /ChE check mobile: 
  
We have decided on using new device called ChE check mobile for our study which is 
developed by Bundeshwehr institute of toxicology and pharmacology for field testing 
along with the manufacturer securetec Detektions- Systeme AG, Brunn- thal.  This 
system also works on the principle of Ellman method (5).  
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Figure 4:  components of the ChE check mobile system  
 
The above figure shows reagent kits for AChE and BChE. Every kit had 100 sample vials 
(2 ml of assay buffer in each vial with white cover), there are 100 red colored reagent 
caps for AChE and equal yellow colored caps for BChE, glass capillaries with EDTA are 
present for blood sampling.  
 
The parts of ChE check mobile are – touch pad with options menu, data entry, instruction 
for use, temperature sensor, rechargeable battery, charger, internal storage and analysis 
unit for AChE, BChE and hemoglobin based on photometry. 
 
This machine has a good correlation with Ellman method as claimed by the 
manufacturers with r value for ACHE being 0.93 for 10 samples (5).  
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This was further validated by another validation study carried out as a part of dissertation 
done by our senior postgraduate in our center which showed overall correlation of AChE 
of organophosphorus poisoning cases over 7 days between AChE machine and laboratory 
values with a correlation coefficient of 0.868 (p<0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
POINT OF CARE TESTING (POC) - CLINICAL SIGNIFICANCE  
 
It has been seen in many studies that point of care testing can increase accuracy of 
diagnosis and confidence of the treating physician in making decisions in rural settings 
(32).  
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Point of care testing is a new term in Indian context. Most government and rural set up do 
not have laboratory back up to measure AChE or BChE levels to decide on treatment and 
have to back their clinical expertise to make decision. This can lead to unnecessary 
referral, increased expenses due to clinicians fear of the unknown in cases where could 
have been managed as a primary care center. This POC system can also help with early 
referral for patients who at presentation may appear relatively stable at presentation but 
had high risk for IMS and need for ventilation and ICU care. Our Study also intends to 
look at admission AChE to look for prognostication of the patient and thus to decide on 
discharge, in hospital management or referral to ICU facilities.  
 
 
 
 
 
 
JUSTIFICATION FOR THE STUDY  
As discussed in previously mentioned study, organophosphorus compounds are the most 
common form of pesticide consumption with intent of deliberate self harm. Our 
institution is no different in this context and OP poisoning accounts for the maximum 
single cause for of admissions in medical intensive care and high dependency unit.   
Pseudocholinestrase or butyl Cholinesterase is usually measured to ascertain organophosphorus 
poisoning but it is not found to correlate well with the clinical severity of poisoninig.  RBC 
46 
 
cholinesterase however is told to have this correlation in view of the structural similarity to the 
neuromuscular cholinesterase enzyme (33). However, RBC cholinesterase is not routinely 
available in most centers including ours. In this Study we use bed side RBC cholinesterase kit 
which can be used even in rural and remote settings and see if a single admission values of 
AChE can serve as indicator for severity of poisoning and atropine requirements.  
Atropine has been the standard of treatment for anti cholinergic poisonings but its dosing 
schedule and dose requirements in different severity has not been established well. We in our 
study aimed to find the different factors which decide dose requirements for atropine. We aimed 
to identify specific factors like difference in compounds ie Dimethyl or Dimethyl, WHO classes of 
poison, any specific compounds, delay in presentations, presentation AChE or BChE and POP scale 
severity which could decide on dose requirements of atropine.  
We also wanted to assess the morbidity in terms of ventilation rates, infection rates, duration of 
hospital stay and mortalities in patient with OP and carbamate poisoning in current scenario in a 
tertiary institution like ours.  
We also planned to assess patients for signs of atropine toxicity and look if we are over treating 
our patients.  
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METHODOLOGY 
  
SAMPLE AND SETTING 
 
Christian medical college is a teritiary care center in south india in the state of tamilnadu 
with Organophosphorus compound being the commonest form of deliberate self harm. 
We get about 150 cases of organophosphorus and carbamate poisoning per year .   
This study was done over a period of 1 year from June 2016 to June 2017. All the 
patients above the age of 18 years, who had presented to Adult accident and emergency 
department of Christian medical college and hospital, Vellore within this period were 
included for this study. Vulnerable groups were excluded. They should have consumed 
the poison within 24 hours of their presentation to CMC.  
The symptoms and signs of cholinergic activation along with history given by the 
relatives or presentation of insecticide bottles consumed were used to identify the group 
of organophosphate and carbamate poisons. The principal investigator was immediately 
informed about a potential patient for the study by the casualty medical officer or the 
social worker in the accident and emergency department. Principal investigator came and 
assessed the patient for satisfying the inclusion criteria for the study and then consent was 
taken from the patient if he/she was completely conscious and oriented or else it was 
obtained from the immediate relative available at the time of presentation. 
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STUDY DESIGN 
 
The study was a prospective cohort design where patients with Organophosphorus and 
carbamate poison to Accident and emergency department of CMC Vellore were enrolled.  
CASE ENROLLMENT 
Consecutive patients who were admitted to the accident and emergency department with 
organophosphorus and carbamate poisoning were recruited into the study.  
Inclusion criteria-  
 
1> Those with anticholinergic toxidrome or evidence of intake of OP or carbamate as 
brought by relatives in form of bottles or leaflet.   
2> Time of ingestion less than 24 hours  
3> age more than 28 years 
Exclusion criteria- 
 
1> Time of ingestion more than 24 hours from presentation  
2> Treated in another center for more than 24 hours  
3> vulnerable groups 
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DATA AND SAMPLE COLLECTION: 
 
A consecutive sampling strategy was used for this study. All patients with age of 18 years 
or more with OP and carbamate consumption either on basis of toxidrome or bottles or 
leaflets brought by relatives and presented within 24 hours of consumption were recruited 
for the study. A total 60 cases of OP and carbamate poisoning were recruited into the 
study. Consent was obtained at presentation.  
The data collection was done by the principal investigator and followed up the patient 
daily till discharge. The baseline BChE was sent to the laboratory and sample for RBC 
AChE was collected at the same time in an EDTA tube and which was immediately 
transferred to and processed on the machine kept in medical ICU.   
The preliminary data regarding demographic details were collected according to clinical 
research form as decided in the IRB meeting. The Results of RBC cholinesterase were 
not informed to the casualty medical officer. The patients were decontaminated, 
resuscitated and atropine was given according to the accident and emergency guidelines 
and clinical judgment to achieve targets of atropinisation. The atropinisation targets were 
those as defined in review article published by Eddleston(18) . This was followed by 
starting the patient on atropine infusion if clinically required according to the treating 
physician.  
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We did not use oximes which are routinely used in some of the other centers due to 
unproven benefits in Meta analyses and potential harms.  
Patients were then followed up during the hospital stay daily for mortality and morbidity 
in form of ventilation requirements, atropine toxicity, intermediate syndrome and 
duration of hospital stay. 
 
 
 
 
 
 
 
 
 
 
 
 
 ALGORITHM FOR THE STU
 
Figure 5 – Algorithm for the study 
 
 
 
1
•All patients with OP and carbamate poisoning presenting to A and E  department 
within 24 hours are recruited after taking consent
2
•Admission value of  RBC cholinestrase taken and resuscitation initiated 
simultaneously 
3
•Start with 2mg atropine bolus and increamental dose ( dose decided  by the 
treatimg physician)every 5 minutes unless goals of atropinisation are achieved and 
sustained. To note the total dose of atropinisation and factors deciding this 
4
•follow up the patients in the ward and ICU for total atropinr requirments, 
ventilation, intermediate syndrome, mortality and safety  outcomes
DY  
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SAMPLE SIZE: 
 
There are no large studies correlating the RBC cholinesterase and severity of poisoning 
or the atropine requirements. Thus sample size calculation was not possible. Thus it was 
decided in discussion with the guide and head of department to include all consecutive 
cases of organophosphorus or carbamate poisoning presenting within 24 hours of 
ingestion to our institution in the study during the study period of 1 year. There were 155 
cases of organophosphorus and carbamate poisoning who presented during the period of 
jan 1st 2015 to 31st December 2015. We expected to recruit a similar number for our 
study but there were instances where patients presented beyond 24 hours and at times the 
information about suspected OP or carbamate poisoning case was not conveyed to the 
principal investigator.  
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DETERMINATION OF CHOLINESTERASE 
ENZYME LEVELS 
 
 
All the patients in the study had following samples taken at admission. 
 1. RBC AChE levels using RBC AChE rapid check mobile  
 2. Plasma BChE activity using standard laboratory methods  
  
Reference standard used in our biochemistry lab is BChE estimation which is done on plasma by 
modified Ellman’s method. Venous blood sample of 2 ml was collected in a red clotted tube and 
was sent to the lab immediately.  In the method used in our lab we measure hydrolysis of the 
substrate acetylthiocholine (ATCh) by BChE to produce acetate and thiocholine.  The 
Thiocholine produced then binds to 5, 5’- Dithiobis-2-nitrobenzoic acid to form a yellow colored 
acid anion called 5-thio-nitrobenzoic acid. The color produced is measured by the 
spectrophotometer and its intensity is used to express the value of cholinesterase levels.  
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For machine AChE measurements, 2 ml of blood was collected in  an EDTA tube and 
was transferred immediately to medical ICU where the respiratory therapist drew 10 
micro liter of blood into a capillary tube which was EDTA coated and was used and was 
used for estimation of the RBC AChE on blood by modified Ellman method.  
 
DATA ANALYSIS AND STATISTICAL 
METHODS  
Data was collected in the clinical research form (appendix) and was entered using epidata 
software and was analyzed using SPSS software.  
STATISTICAL METHODS 
Data were screened for outliers and extreme values using Box-Cox plot and histogram 
(for shape of the distribution). Summary statistics were used for reporting demographic 
and clinical characteristics. t-test was used for analysis of continuous data with Normal 
distribution and Mann-Whitney U test for data with non- Normal distribution. Chi-square 
test was performed for categorical variables and the variables which were significant at 
Bi variate analysis were assessed by multivariate analysis. Differences were considered 
significant at p value of <0.05. 
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FUNDING AND APPROVAL  
 
A fluid research grant was obtained from the institution and was used only for the 
printing of the dissertation. There was no external funding for the study.  
The ACHE point of care machine which was used in the study was purchased for a 
previous study done by another medicine post graduate and needed  no funding for the 
current study  
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INSTITUTIONAL RESEARCH BOARD 
APPROVAL AND ETHICAL 
CONSIDERATIONS 
 
 
 
The research proposal for this study was discussed by the Institutional Review Board in 
2016 and approval was obtained [IRB Min. No.10020 Dated 04.04.2016]. There were no 
ethical issues related to this study. Institutional review board approval was obtained for 
the procedures. 
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RESULTS  
DEMOGRAPHIC CHARACTERISTICS OF PATIENTS WITH 
ORGANOPHOSPHORUS AND CARBAMATE POISONING 
 
60 patients with age above 18 years who came to the accident and emergency department 
of CMC Vellore and gave their written consent were included in this study. Mean age of 
the patient was 30.63 years. There were total 43 men (71.66%) and 17 women 
(28.33%).The mean age (± SD) of males was 32.65 ±15.18 and for females was 25.13 
±7.10. 78.3  percent of patients were younger than 35 years 
  
 Table 5 : Age distribution of patients  
  Frequency Percent Valid Percent 
Valid <25 24 40.0 40.0 
26-35 23 38.3 38.3 
36-45 4 6.7 6.7 
>45 9 15.0 15.0 
Total 60 100.0 100.0 
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ORGANOPHOSPHORUS COMPOUND 
CHARACTERISTICS  
 
A compound was identified in 49 (81.7 %) out of 60 cases. In 81.6 % of cases the 
compound was identified by the bottle of the pesticide which was brought by the 
patient’s relatives, 5 by the leaflet which was brought by the relatives(10.2%) and in 4 
by the compound name was given by the patient or bottle identified by patient (8.2%). 
In 11 cases the diagnosis of OP poisoning was based on clinical criteria of diagnosis 
(history of pesticide ingestion or typical toxidrome with low BChE levels). 
 
The most commonly consumed compounds in rank order were Monocrotophos (10), 
chlorpyrifos (9), Phorate (8) and Profenofos (6). Carbofuran was the commonest 
carbamate (4). Other pesticides consumed were triazohphos (1), Dimethoate (2), 
Dichlorvos (2), Quinalphos (1), and Malathion (1). 38.77 % of the compounds were 
Dimethyl OP compounds and 53.06 % diethyl OP compounds and 8.16 % carbamate 
compounds.  
Most poisons were either WHO class 1(51%) or Class 2(46.9), in a date where class 1 and 
class 2 poisons are banned in many countries by legislatures. 
 
Table 6: who class of poison 
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 Frequency  Percent 
 WHO 
class 1 
25  51.0 
WHO 
class 2 
23 46.9 
WHO 
class 3 
1 2.0 
Total 49 100.0 
 
In 6 out of 49 identified compounds patient had taken a combination of 
organophosphorus with pyrethroid. The pyrethroid was cypermethrin in 8 out of 9 
cases.  There were also cases with poisonings mixed with other classes of compounds 
like alprazolam and imidacloprid (1 case each).  
Table 7: Method of identification of compounds  
 Frequency Percent 
 
Informed by 
patient 
4 6.7 
Leaflet 5 8.3 
bottle  brought 
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TREATMENT RECEIVED OUTSIDE 
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50 out of 60 patients who presented to CMC had some form of treatment or 
decontamination done prior to presentation. None of them had a skin decontamination 
given. 71.6% had a gastric lavage done outside and 20% had an induced emesis done 
which was mostly by use of salt.   
36 of out of 60 patients had received some dose of atropine before presentation (60%) 
and 6 patients had received 1
st
 dose of oximes (10%). 4 Patients presented intubated from 
outside.  
The mean delay of presentation from consumption was 5 hours. However, this duration 
cannot be taken as very reliable as it was the approximate time of consumption as given 
by relatives and at times patients were found unconscious and the poisoning was not 
witnessed.  
Table 8: Treatment received outside  
Form of outside treatment  Frequency  
Induced emesis  12 (20%) 
Gastric lavage  43(71.7%) 
Atropine  36(60%) 
Oximes  6(10%) 
Intubation  4(6.7%) 
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TOXIDROME AT PRESENTATION  
The majority of patients had a typical toxidrome of presentation. The SLUDGE 
symptoms were common. Their frequency was salivation (51.7%), lacrimation (15%), 
urination (33%), loose stool (41.7%) and vomiting (81.7%). About half the patients; 28 of 
50 had altered sensorium at presentation. 40 percent were breathless and 10 percent had 
generalized fasciculation. None of the patients had seizures at presentation which is a 
sign of severity of poisoning according to POP scale. 
Table 9: Symptoms at presentation  
Salivation 31(51.7%) 
Lacrimation 9(15%) 
Frequency of urination 20(33.3%) 
Loose stools  25(41.7%) 
Vomiting   49(81.7%) 
Seizures  0(0%) 
Breathlessness  24(40%) 
Altered sensorium  28(46.7%) 
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Fasciculation 6(10%) 
  
SIGNS AT PRESENTATION 
Signs at presentation Number of patients(percentage) or mean 
(+/- SD ) 
Pulse rate 104(27.63) 
Systolic blood pressure  112(28.1) 
Respiratory rate  23.5(8.3) 
GRBS  140.65(63.94) 
Constricted pupil(<2mm) 29(49.2%) 
Diaphoresis  21(35.6%) 
Lung crepitations 25(41.7%) 
Salivation  25(41.7%) 
Frothing  17(28.3%) 
Fever  2(3.3%) 
Fasciculation 13(21.7%) 
Abdominal tenderness  4(6.7%) 
Paradoxical breathing  16(27.1%) 
Table 10: signs of organophosphorus and carbamate poisoning at presentation 
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Papillary constriction was the commonest sign noticed at admission followed lung 
crepitations, salivation and diaphoresis.  
Fasciculation was also a common sign of organophosphorus poisoning (21.7%)  
 
SEVERITY OF POISONING  
 
Peradeniya organophosphorus poisoning (POP) scale is a validated scale to assess the 
severity of organophosphorus poisoning and was used in this study.  
Table 11: severity of organophosphorus poisoning  
POP scale severity  Number of patients  Percent 
 
Mild 
35 58.3 
Moderate 22 36.7 
Severe 3 5.0 
Total 60 100.0 
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Table 12: Sensorium of patients at presentations (Glasgow coma scale) 
 
 
 
 
 
 
 
 
  
       
 
 
 
 
 
 
 
 
 
 
 
 
GCS   Frequency Percentage 
 
 
 
<8 18 30.5 
8-12 3 5.1 
   
>=13 38 64.4 
Total 59 100.0 
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DESCRIPTION OF TREATMENT  
 
(10%) received gastric lavage at admission to CMC emergency department and only 4 
received activated charcoal. Those who presented late did not receive gastric lavage. 
43 out of 60 had already received lavage elsewhere. The mean initial atropine dose for 
achieving targets of atropinisation was 34.7 ml and atropine infusion with an average 
dose of 219 ml and average duration of atropine infusion for 2.7 days was required 
during the study. 20.3% developed atropine delirium and needed chemical or 
mechanical restraints.  
 
Table 13: Treatment at presentation  
 Frequency(percentage) or Mean (+/- SD ) 
Activated Charcoal  4(6.7%) 
Gastric lavage  6 (10%) 
Initial atropinisation dose  34.7 ( +/- 52.7) 
Total Atropine dose  219.4 (+/- 242) 
Duration of atropine  2.7 (+/- 1.7 ) 
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CLINICAL OUTCOME AND COMPLICATIONS 
========================================= 
 
 
30 % of patients developed intermediate syndrome and average duration of intermediate 
syndrome was 8 .3 days. 55 % patients required both ICU admission and mechanical 
ventilation of which 23.3 % required tracheostomy for prolonged ventilation. The most 
common indications for mechanical ventilation were low sensorium and respiratory 
muscle weakness. The mean duration of ventilation was 8.6 days and mean duration of 
hospital stay was 8.4 days.   
38.3 % patients developed nosocomial infections which were most commonly (21 out of 
23 cases) ventilator associated pneumonias. 2 patients had catheter associated urinary 
tract infection. There were no catheter related blood stream infections in our clinical 
cohort.  
5 patients had bacteremia with causative agent being klebsiella (2), staphylococcus 
aureus (1), acinetobacter (1) and unidentified Non fermenting gram negative bacilli (1).  
Klebsiella, acinetobacter, pseudomonas and unidentified non fermenting gram negative 
bacilli were commonly cultured from endotracheal aspirate of patients with ventilator 
associate pneumonia. Of the 60 cases, 53 patients recovered completely (88.3%), 4 
patients were discharged against medical advice (6.7 %) and 3 patients died during 
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hospitalization (5%). One patient died during the cholinergic crisis and two patients died 
of hospital acquired infections. 
Table 14: Complications  
 Number of patients( percentage or +/-SD) 
Intermediate syndrome 18(30%) 
ICU admission 33(55%) 
Duration of hospital stay  8.4(+/- 6.8%) 
Need for Mechanical ventilation  33(55%) 
Need for Tracheostomy   14(23.3%) 
Infective complication 
               Ventilator associated pneumonia 
                UTI  
                Bacteremia   
23(38.3%) 
21(35%) 
2(3.3) 
5(8.3%) 
Atropine delirium  22(36%) 
Cardio respiratory arrest  3 (5%) 
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Table 15: stratification 
of duration of 
ventilation by days  
 
 
 
 
Low sensorium and respiratory failure were the commonest indication for ventilation. 
Most patients who were ventilated for less than 5 days were the ones who were intubated 
for acute cholinergic crises.  
Longer duration ventilation was in ones who had intermediate syndrome or had ventilator 
associated pneumonia.  
 
 
 
 
Duration of 
ventilation 
 
Frequency Valid Percent 
 <5 11 36.7 
5-10 9 30.0 
>10 10 33.3 
Total 30 100.0 
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Table 16 : Clincal outcomes 
Outcome  
       Alive  
        Death  
       DAMA  
 
53 (88.7%) 
3 (5%) 
4 (6.7%) 
 
 
Correlation between RBC cholinesterase at admission 
and severity and requirements of atropine for 
treatment 
 
 
Table 17: RBC cholinesterase correlation with POP severity scale 
POP severity scale Mean Median Std. Deviation 
Mild 17.335 8.450 16.9031 
Moderate 5.527 1.550 9.7377 
Severe 2.167 2.000 1.2583 
Total 12.161 4.000 15.3134 
 
 
An ANOVA analysis of correlation between RBC cholinesterase levels and severity of 
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poisoning according to POP class showed that there was significant difference of RBC 
cholinesterase levels between the POP classes.  
The P value was 0.008 
 
 
 
 
 
Table 17: ANOVA Table for RBC cholinesterase and POP classes of severity 
   
Sum of 
Squares df 
Mean 
Square F Sig. 
RBC 
cholinesterase * 
POP severity scale 
Between 
Groups 
(Combined) 
2178.092 2 1089.046 5.339 .008 
Within Groups 11423.008 56 203.982   
Total 13601.100 58    
 
 
 
 
There was also a significant negative correlation between admission level of RBC 
cholinesterase and the initial atropinisation dose and also the total requirement of atropine 
during admission.  
Measures of Association 
 Eta Eta Squared 
RBC cholinesterase *   
POP severity scale 
.400 .160 
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Table 19: Correlation between RBC cholinesterase and initial 
atropinisation and total dose 
  RBC 
cholinesterase 
initial dose of 
atropine 
RBC cholinesterase Pearson Correlation 1 -.405
**
 
Sig. (2-tailed)  .001 
N 59 59 
initial dose of 
atropine 
Pearson Correlation -.405** 1 
Sig. (2-tailed) .001  
N 59 60 
**. Correlation is significant at the 0.01 level (2-tailed).  
 
 
  RBC 
cholinestrase 
total dose of 
atropine 
RBC cholinesterase Pearson Correlation 1 -.503** 
Sig. (2-tailed)  .000 
N 59 58 
total dose of 
atropine 
Pearson Correlation -.503
**
 1 
Sig. (2-tailed) .000  
N 58 59 
**. Correlation is significant at the 0.01 level (2-tailed).  
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Figure 6: correlation between RBC cholinesterase (y-axis) in unit/gm Hb and total dose 
of atropine in ml.  
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The differences in atropine requirements for initial 
atropinisation and outcomes in different severity of op 
poisoning using Peradeniya organophosphorus 
poisoning (POP) scale 
 
There was significant difference between the initial atropine requirements in between the 
three classes of patients on the basis of POP severity scale.  
 
     
POP 
severity 
scale Mean Median Std. Deviation Minimum Maximum N 
Mild 14.97 .00 22.534 0 64 35 
moderate 51.95 31.50 62.095 0 256 22 
Severe 138.67 134.00 81.101 60 222 3 
Total 34.72 10.00 52.721 0 256 60 
 
Intermediate syndrome was much more common in patient with moderate (45%) and 
severe (33%) classes as compared to mild severity (20 %). 
All patients in severe class and 91 percent of patients in moderate severity needed 
mechanical ventilation as compared to 28.6 percent in the mild severity group.  
Table 20 : initial dose of atropine and  severity by POP scale 
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All patients (3) in severe group and 19 out of 22 patients in moderate severity (86%) 
classes needed ICU admission while 11 out of 35 cases in mild class of POP (31.4%) also 
needed  ICU care. 
Patients with severe poisoning needed a mean dose of 138 ml of atropine for initial 
atropinisation as compared to 51 and 15 ml in moderate and mild severity classes.   
 
All these correlations between POP classes of severity of poisoning and atropine 
requirement and also measures of outcomes – Intermediate syndrome, mechanical 
ventilation and need for ICU stay were statistically significant.  
Table 21: Correlation between severity by POP scale and complications 
complications in number 
(percentage)  
MILD  
(n=35) 
MODERATE  
(n=22) 
SEVERE  
(n=3) 
Intermediate syndrome 7 (20 %) 10 (45.5%) 1 (33.3 %) 
Intubation 10(28.6%) 20 (90%) 3 (100%) 
ICU admission  11(31.4%) 19 (86.4%) 3 (100%) 
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ANOVA Table 
   Sum of 
Squares Df 
Mean 
Square F Sig. 
initial dose of atropine * 
POP severity scale 
Between 
Groups 
(Combined) 
52599.591 2 26299.795 13.458 .000 
Within Groups 111390.593 57 1954.221   
Total 163990.183 59    
 
Measures of Association 
 Eta Eta Squared 
initial dose of atropine * 
severity by  POP 
severity scale 
.566 .321 
 
 
 
Table 22 : Correlation between 
POP scale and initial dose for 
atropinisation 
    
sev  POP 
severity 
scale Mean Median Std. Deviation Minimum Maximum N 
Mild 14.97 .00 22.534 0 64 35 
moderate 51.95 31.50 62.095 0 256 22 
Severe 138.67 134.00 81.101 60 222 3 
Total 34.72 10.00 52.721 0 256 60 
76 
 
ASSCIATION BETWEEN 
PSEUDOCHOLINESTRASE AND OUTCOMES 
AND SEVERITY OF POISONING  
 
There was no significant association between mean value of pseudo cholinesterase level 
at admission between  intubated and non intubated  groups, when a T-test was done for 
the equality of means with p value of 0.67 (when equal variance was assumed).  
No significant association was noted for pseudo Cholinesterase levels at admission and 
ICU admission on doing a T test for equality of means with P value of 0.067  
Pseudo cholinesterase levels and severity by POP severity scale (mild as compared to 
moderate and severe combined) was also not found to have any statistically significant 
association (P value 0.35) 
Table 23: correlation between pseudo cholinesterase and ventilation  
 
ventilation N Mean Std. Deviation 
Std. Error 
Mean 
Pseudo 
cholinesterase 
Not 
intubated 
26 2845.27 3315.817 650.285 
intubated 33 1222.55 3310.711 576.321 
 
T test for equality of means had P value of 0.067 
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Table 24: Correlation between pseudo cholinesterase level at presentation and ICU 
requirement 
 ICU 
admission Number Mean Std. Deviation 
Std. Error 
Mean 
Pseudo 
cholinesterase 
No 26 2844.31 3316.628 650.444 
Yes 33 1223.30 3310.460 576.277 
T test for equality of means had P value of 0.067 
 
Table 24: Correlation between pseudo cholinesterase levels at presentation and POP 
scale of severity (mild and non mild i.e. moderate and severe) 
 
POP N Mean Std. Deviation 
Std. Error 
Mean 
Pseudo 
cholinesterase 
Mild 34 2291.12 3158.770 541.725 
Moderate/severe 25 1456.92 3677.702 735.540 
 T test for equality of mean when assumed equal variance, P value = .354  
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IMPLICATIONS OF THE STUDY  
The study has demonstrated that the point of care AChE measurement can be reliably 
used to diagnose and also assess severity of organophosphorus poisoning. Most primary 
and secondary centers in India even till date do not have RBC or Pseudo cholinesterase  
testing facilities and this hand held device could be used even in small settings. This can 
make referral process faster in cases where low RBC cholinesterase needs tertiary or 
secondary care management. Even where tests are available the turnaround time for 
results are slow and hence the results of the test cannot be used for clinical decision 
making. The RBC Check mobile can be useful in primary health centre, district hospitals 
and taluk hospitals for 
The study also shows the need to classify patients by use of POP scale at admission and 
which identifies the sick patients needing ICU care and ventilation.  
The main implications in points are –  
 
(1)Use of RBC cholinesterase for diagnosis of OP poisoning  
 
 (2)  Triaging Patients with very low AChE for transfer to an ICU care setup equipped for 
mechanical ventilation. 
 
(3) Triaging on basis of POP severity scale at admission with moderate and severe POP 
class cases to be admitted directly to ICU care setup. 
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DISCUSSION 
 
Organophosphorus and carbamate are the commonest poisoning seen in our emergency 
department on daily basis. Atropine is the only known specific treatment for them along 
with supportive management. The role of oximes is controversial and meta analysis even 
have shown harm with it.  Pseudo cholinesterase is the current standard followed in most 
centers for the diagnosis of anti cholinesterase poisoning (OP and carbamate). Pseudo 
cholinesterase levels correlate poorly with clinical severity and outcome in patients. RBC 
cholinesterase has shown to correlate with neuromuscular weakness as shown by 
Thiermann et al in a small study. We used a hand held device (RBC ACHE check device) 
to measure RBC cholinesterase at admission and also looked at severity and outcomes 
and their correlation.  
This aim of the study was to assess the dose and determinants of atropine requirement 
and outcomes in organophosphorus and carbamate poisoning and it fulfilled most of it 
through the below mentioned objectives.   
Objective 1 
 
To assess the correlation between RBC cholinesterase at admission and severity and 
requirements of atropine for treatment 
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The admission RBC cholinesterase has a significant negative correlation with severity by 
POP classes, the initial dose needed for atropinisation as well as the total atropine 
requirement. 
Admission pseudo cholinesterase checked simultaneously lacked these correlations to 
predict severity and need for higher doses of atropine.  
We thus propose that RBC cholinesterase be used universally as a marker for 
organophosphorus and carbamate poisoning and that it should replace the usual standard 
of cares i.e. Pseudo cholinesterase in our center.  
 
 
Objective 2  
 
 To assess the dosing and various factors which determine the atropine requirement in 
organophosphorus and carbamate poisoning. 
This study showed a mean dose of atropine needed was 34.7 ml and a total mean dose of 
219.3. The mean duration for which atropine infusion was continued was for 2.7 days.  
RBC cholinesterase levels, POP scale severity were found to correlate with the atropine 
requirements.  
 
Objective 3 
3) To assess rates of ventilation, mortality, rates of intermediate syndrome and duration 
of hospital stay in the same patients 
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3 out of our 60 patients died during the hospitalization. Our mortality rate for OP and 
carbamate poisoning was 5 percent which is lower than those described in literature in 
past ranges from 10 to 33 percentages (34) (35) (36) .  This reflects the presence of good 
quality ICU back up care in our set up.  
The rate of ventilation was 55 percentage, this could be due to referral bias and patients 
needing ventilation referred to our center due to availability of an intensive care unit. 19 
of the 33 patients who were initially intubated went on need tracheostomy for prolonged 
ventilation in view of intermediate syndrome or ventilator associated pneumonia. The 
mean duration of ventilation was 8.7 days with a minimum requirement of 2 days and a 
maximum of 18 days.  
Intermediate syndrome was diagnosed in 18 out of 60 patients (30 percentage) 
The mean duration of hospital admission was 8.4 days and maximum of 26 days in 1 
patient with multiple complications. 
 
Objective 4 
 
Assess for possible atropine toxicities in form of delirium and hallucinations and 
requirement of physical and chemical restrains by using Confusion assessment method 
 
The assessment of atropine toxicities could be done only in patients who were not 
intubated as patients on ventilator invariably needed sedation and restrains. 
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 24 out of 36 patients had some form of delirium or hallucinations. All of them needed 
some form of restrains. The chemical restrains used were short acting benzodiazepine 
midazolam. The physical restrains used were for the hands and feet after obtaining a 
consent from relatives. 60 percent had delirium or hallucinations which is a high 
percentage of patients. 
This could represent over use of atropine. Another point of view is that does it occur even 
at normal therapeutic doses of atropine needed for treatment. This needs further studies 
for clarification. A potential use of glycopyrrolate could avoid this side effect but its high 
cost prevents its routine use. No severe toxicity of atropine was noted in form of any 
arrhythmias or myocardial infarction and the delirium gradually resolved in all patients 
with reducing the infusion rate or stopping the drug.  
 
Objective 5  
 
The differences in atropine requirements for initial atropinisation and outcomes in 
different severity of op poisoning using Peradeniya organophosphorus poisoning 
(POP) scale  
 
The mean initial atropinisation doses in mild, moderate and severe classes of POP 
severity were 15ml, 52 ml and 139 ml respectively. There was statistical difference in 
atropine requirements of the three classes. 
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Intermediate syndrome was commonest in moderate severity group with 45.5 percent of 
patients having it as compared to 33.3 percent in severe and 20 percent in the mild POP 
class. The low rate of intermediate syndrome seen in severe class may be due to the low 
number of patients in this group with only 3 patients in severe class.  
 
Ventilation requirements were 100 percent in the severe class of POP as compared to 
90.9 percentage in moderate and 28.6 percentage in the mild POP class. 
 
All patients in severe POP class needed ICU admission as compared to 86.4 percentage 
in moderate and 31.4 percent in the mild POP class.  
 
These findings further validate and strengthen the need for classifying patients at 
admission and consider early referral at smaller centers as patients in moderate and 
severe category need ICU care and intubation in most cases.  
We also propose a new system of triage on this basis and propose that all patients in 
severe and moderate POP class of poisoning be directly admitted in ICU for most 
probable need for ventilation and monitoring.  
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FUTURE SCOPE AND RECOMMENDATIONS  
 
1. To explore making this machine available in a cost-effective manner in the government 
health system.  
2. Replace pseudo Cholinesterase with RBC cholinesterase for diagnosis and 
prognostication of organophosphorus and carbamate poisoning on institutional and 
national basis.  
3. A field level feasibility study at primary and secondary hospital level in diagnosing 
and managing Organophosphorus poisoning.  
 
4. Use of POP scale in patients with clinical features of Organophosphorus poisoning if 
RBC cholinesterase tests not available 
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LIMITATIONS OF THE STUDY   
 
 
1) We could only include 60 patients in the study as compared to around 150 patients 
with OP poisoning which are admitted in Christian medical college every year. This was 
due to the fact that some patients came beyond the period of 24 hours after consumption.  
There were also some cases which were missed as the principal investigator was not 
informed in time to collect the admission sample of RBC cholinesterase.  
 
2) Poison could not be identifies in 11 of the 60 cases of poisonings with clinical 
syndrome and pseudo cholinesterase consistent with anti cholinesterase poisoning.  
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CONCLUSION  
 
This study was conducted in a tertiary setup in southern India in CMC vellore. We looked 
at consecutive cases of organophosphorus and carbamate poisoning presenting within 
24hours of consumption. We looked and found a good negative correlation between 
admission RBC acetyl cholinesterase levels and severity of poisoning. Low RBC 
cholinesterase levels were also associated with more complications like need for 
ventilation and ICU stay. It also correlated with need dose of atropine for initial 
atropinisation and then total dose of atropine required.  We also found admission pseudo 
cholinesterase not to correlate with severity, atropine requirements and complications. 
We thus propose the use of RBC cholinesterase for diagnosis and prognostication of 
organophosphorus and carbamate poisonings.  
 
The Peradeniya organophosphorus scale is a severity scale which is validated in past. We 
found it to correlate well with RBC cholinesterase levels and also need for ICU stay, 
ventilation and atropine requirements. Thus, we propose that POP severity scale be used 
for assessment in every patient at presentation and that  it be used as a triage tool in 
primary and secondary set up to assess the need for urgent  referral in patients in 
instances where RBC cholinesterase test is unavailable.  
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ANNEXURES 
 
 ANNEXURE 1 – PATIENT INFORMATION SHEET  
 
Study Title:  The dose and determinants of atropine requirements and outcomes in 
acute organophosphate and carbamate poisoning 
 
Subject’s Name: _________________________________________  
Date of Birth / Age: ___________________________  
 
Your relative has been admitted with poisoning due to Organophosphorus or 
carbamate insecticides. This poisoning needs supportive care like medicines to 
neutralise the effect of poison, monitoring and respiratory supports whenever 
required. These poisons act by blockage of enzymes in the brain and nerves 
causing various symptoms like sweating, vomiting, loose stools, excessive 
urination, weakness and breathing difficulty. The name of the protein that is 
blocked is cholinesterase. Atropine has been used in treatment of this poisoning 
and is absolutely necessary. However, the optimum dose and frequency of this 
drug is not well established. This study aims to find the dose and determinants of 
atropine requirement in these poisoning.   
Participation in the study is purely voluntary and you can decide to withdraw your 
relative from the study at any time. Your relative will receive all standard 
treatment according to hospital protocols and your doctor will decide on the 
optimum treatment for your relative. This is a purely observational study and does 
not involve any additional drug treatment apart from the standard treatment. This 
study will not in any way influence the treatment that your relative is receiving in 
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the hospital. All the patient‘s health records and any other data arising from the 
study would be kept confidential and used only for scientific purposes.  
Inclusion into this study involves signing a consent form and the following:  
1. Collection of clinical data including details of poisoning  
2. Daily clinical examination (which is a part of routine care)  
3. Blood tests ( No additional tests for the study) 
 The procedures of the study not painful and do not cause any threat to health. 
Please contact me if you have any doubts. (Dr Avanish Jha ,PG registrar , General 
medicine.  Phone No 8056966200 ) 
ANNEXURE 2 – INFORMED CONSENT FORM 
Informed Consent form   
 
Study Title: Study Title:  The dose and determinants of atropine requirements 
and outcomes in acute organophosphate and carbamate poisoning 
 
Study Number: ____________ 
Subject’s Initials: __________________ Subject’s Name: 
_________________________________________ 
Date of Birth / Age: __________________________ 
 
(i)  I confirm that I have read and understood the information sheet dated 
____________ for the above study and have had the opportunity to ask 
questions. [  ] 
(ii)  I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. [  ] 
92 
 
(iii)  I understand that the Ethics Committee and the regulatory authorities will 
not need my permission to look at my health records both in respect of the 
current study and any further research that may be conducted in relation to 
it, even if I withdraw from the trial. I agree to this access. However, I 
understand that my identity will not be revealed in any information released 
to third parties or published. [  ] 
(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). [  ] 
(v)  I agree to take part in the above study. [  ] 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________         Signature:  
 
Or 
 
 
 
 
Representative: _________________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
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Study Investigator’s Name: _________________________ 
 
 
Signature or thumb impression of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name & Address of the Witness: ______________________________ 
 
 
ANNEXURE 3 – CLINICAL RESEARCH FORM 
                            
 
 Clinical research form          Serial number 
 
Ascertainment criteria for OP poisoning (Tick appropriately): 
1. Patients who present with history of pesticide poisoning with an identified OP compound. 
2. Patients who present with history of pesticide poisoning with typical toxidrome of organophosphate 
poisoning, and low pseudocholinestrase levels 
Informed consent obtained: Yes/No 
DEMOGRAPHIC DETAILS                          
1.  Name: 
 
2. Hospital  ID: 
 
3. Age: 
 
4. Sex:          1.Male / 2.Female 
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5. Marital status:         1.married / 2. Single / 3. Others 
 
6. Education:        1.Uneducated / 2.Educated   
 
Profession: 1.Unskilled/2.Semi-skilled/3.Skilled COMPOUND 
 
1. Compound identified:  Yes / no  
 
2. Compound  name:  
 
3. Method by which compound identified: Name given by patient/leaflet/bottle brought 
 
4. Type of compound : 1. Dimethyl  /  2. Diethyl  / 3. Others 
 
5. Percentage of compound : 
 
6. Compound quantity(volume):  
 
DETAILS  REGARDING INGESTION 
 
7. Time and date of consumption:                                     
 
8. Time and date of First medical contact: 
 
9. Time and date of arrival ay CMC: 
 
10. Treatment given outside  :  1. Skin decontamination  /  2.Induced Emesis  /  3.  Gastric Lavage/ 
 
 4. Atropine  /  5. PAM  / 6.Intubation 
 
11. Toxidrome:  1. Salivation / 2. Lacrimation / 3. Urination / 4. Defaecation / 5. Vomiting / 6.Seizures /  
 
7. Breathlessness / 8. Fasciculations / 9.Altered sensorium 
 
12. Severity of poisoning by POP scale:  Mild/Moderate/Severe 
 
 
 
CLINICAL FEATURE – ON ADMISSION IN E&D 
 
1. GCS at presentatation: 
 
2. Pupils size:            PINPOINT / DILATED/ NORMAL (2-5MM) 
 
3. Pulse rate at presentation: 
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4. Blood pressure at presentation: 
 
5. Respiratory rate at presentation: 
 
6. Saturation at presentation: 
 
7. GRBS 
 
 
 8. Symptoms at presentation 
Vomiting/diarrhoea/abdominal pain/salivation/sweating/ urinary incontinence                    
/drowsiness/breathing difficulty/seizures/bleeding/giddiness/altered sensorium /agitation/blurring of 
vision/ sedation/asymptomatic 
9.Signs at presentation 
Diaphoresis 
Pupil size  
Lung crepitations 
Salivation 
Frothing at mouth 
Fasiculations/muscle weakness 
Single breath count 
Paradoxical breathing 
Abdominal tenderness 
Fever 
10.Investigations 
         Laboratory pseudocholinestrase levels: 
        Bed side RBC cholinesterase levels: 
12. Serial clinical assessment 
Heart rate DAY1 2 3 4 5 6 7 
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Blood pressure        
GCS        
MUSCLE 
POWER- 
upper limb 
proximal  
distal  
lower limb 
proximal  
distal  
neck power 
flexion 
       
        
Neck Muscle 
weakness-neck 
holding time 
Respiratory 
muscle 
weakness 
Tidal volume 
Pressure 
support 
PEEP 
Single breath 
count 
       
Miosis        
Crepitations        
Salaivation        
Diarrhea        
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Cholinergic 
crises 
present/absent 
       
Atropine 
infusion rate 
       
Total atropine 
dose 
       
Sedation or 
restrains 
present/absent 
       
Intermediate syndrome: Present/absent 
Duration of intermediate syndrome: 
13.Atropine requirement for initial atropinisation: 
14. Did the patient Required ICU admission 
15.Date of admission                                               date of discharge 
 
16.Did the patient require  ventilator support? 
17.Date intubated                                     Time intubated 
18.Indication for mechanical ventilation 
19.Duration of mechanical ventilation 
 20.Did the patient require  tracheostomy   yes no 
20.Duration of ICU stay. 
21.Complications 
Cardiac arrest-yes/no 
Respiratory arrest-yes/ no 
Infective complications-yes/ no What infection: 
Criteria for diagnosis of infection: 
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Chest x-ray 
Cultures: 
 
22. Treatment: 
Gastric lavage at CMC: Yes/No 
Charcoal at CMC: Yes/No 
Atropine: Yes/No  Duration (in days): 
Total dose of atropine: 
23.Death – yes/ no 
24. Cause of death: 
Cholinergic crises 
Ventilatory and airway problems: 
Infections: 
25. delirium at any time during admission ( as defined by CAM) 
26. Any need for chemical or mechanical restraints at any point: 
Summary data: 
OP compound: -------------------------/ Unknown Concentration:   Volume: 
Severity of poisoning: Mild/Moderate/Severe 
Cholinergic crises present/absent Duration of cholinergic crises: 
Atropine duration:  Total atropine dose:  
GCS at admission: 
Duration of low GCS: 
Requirement of mechanical ventilation: Yes/No 
Duration of mechanical ventilation: 
Intermediate syndrome: Yes/No 
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Duration of intermediate syndrome: 
Delirium at any time 
Duration of hospitalisation 
Final outcome: Alive/ Dead/ Discharged against medical advise 
 
Name of person who filled the form and signature: 
ANNEXURE 4 - STANDARD OPERATING PROTOCOL FOR DETERMINATION 
OF CHOLINESTERASE STATUS IN WHOLE BLOOD AND PLASMA 
MATERIALS REQUIRED FOR THE ASSAYS  
 
1) Phosphate buffer (= PP, 0.1 M, pH 7.4)  
Solution 1: Na2HPO4*2H20, MW 177.9 (17.8 g in 1000 ml distilled water)  
Solution 2: KH2PO4, MW: 136.1 (13.6 g in 1000 ml distilled water)  
800 ml of solution 1 was mixed and adjusted with solution 2 to pH 7.4 with pH-meter and 
filtrate and stored in amber bottle at +4°C.  
2) Diluting reagent for blood dilution: Distilled water  
3) 5,5´-dithio-bis(2-nitrobenzoic acid) (= DTNB, Ellman´s reagent)  
396.3 mg DTNB (MW 396.3, Sigma) was dissolved in 100 ml of phosphate buffer (0.1 
M, pH 7.4) and stored aliquots at ≤-20°C. The concentration is 10 mM in the solution and 
0.3 mM in the cuvet.  
4) Acetylthiocholine iodide (=ASCh)  
41.12 mg ASCh (MW 289.2, Sigma) was dissolved in 5.0 ml distilled water and stored 
aliquots at ≤-20°C. The concentration is 28.4 mM in the solution and 0.45 mM in the 
cuvet.  
100 
 
5) S-Butyrylthiocholine iodide (= BuSCh)  
200.47 mg BuSCh (MG: 317.2, Sigma) was dissolved in 10.0 ml distilled water and 
stored in aliquots at ≤-20°C. The concentration is 63.2 mM in the solution and 1.0 mM in 
the cuvet.  
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6) Ethopropazine (selective BChE inhibitor) 20.94 mg ethopropazine hydrochloride 
(MW 348.94, Aldrich) was dissolved in 10 ml of 0.01 M HCl under stirring and mild 
heating and stored in aliquots at ≤-20°C. The concentration is 6.0 mM in the solution and 
0.02 mM in the cuvet.  
7) Transformation solution  
200 mg K3[Fe(CN)6] (MW 329.2), 50 mg KCN (MW 65,1), and 1000 mg NaHCO3 
(MW 84.0) were mixed with 1000 ml distilled water, followed by 0.5 ml Triton X-100 
and stored in a tightly sealed amber glass bottle at ambient temperature.  
8) Diluting reagent for test erythrocytes  
100 μl Triton X-100 (Sigma) was added to 100 ml phosphate buffer (0.1 M, pH 7.4) and 
mixed thoroughly with final concentration of Triton X-100 at 0.1%  
9) Test erythrocytes and test plasma  
Blood was taken in EDTA tube, centrifuged (10 min, 3000 rpm) and transfer plasma into 
tube (―test plasmaǁ). The dilute packed erythrocytes with PP were mixed, centrifuged 
and supernatant was removed. This was repeated three more times. Washed, packed 
erythrocytes were diluted with 10 volumes diluting reagent for test erythrocytes and 
mixed. Aliquots of test erythrocytes and test plasma were transferred in separate tubes 
and stored at ≤-20°C.  
10) Cuvets: Polystyrene cuvets (10 x 10 x 45 mm, e.g. VWR 634-0675)  
MEASUREMENTS IN THE ASSAYS  
a) Haemoglobin content  
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Sample preparation: 0.3 ml of the blood dilution and 2.7 ml of the transformation 
solution were mixed in a cuvet and extinction was read after 10 min against a reference 
cuvet containing only transformation solution.  
Conditions: Wavelength: 546 nm, Temperature: Ambient, Extinction coefficient: 10.8 * 
103M-1cm-1, Cuvets with 1 cm light path  
Calculation: μM Hb* = - extinction (mA)  
----------------------------------------  
10.8* molarity refers to iron  
b) Erythrocyte AChE activity  
Conditions: Wavelength: 436 nm, Extinction coefficient: 11.28 * 103M-1cm-1, 
Temperature: 37°C, Cuvet volume: 3.16 ml, Recording time: 2 min, Cuvets with 1 cm 
light path  
Substrate blank%:  
- 3000 μl phosphate buffer (PP), 100 μl DTNB, 10 μl ethopropazine, 50 μl ASCh  
- PP, DTNB and ethopropazine were added to cuvet, equilibrated for 10 min, ASCh was 
added and mixed  
Sample:  
- 2800 μl PP, 100 μl DTNB, 200 μl blood dilution (sample), 10 μl ethopropazine, 50 μl 
ASCh  
- PP, DTNB, ethopropazine and sample were added to cuvet, equilibrated for 10 min, 
ASCh was added and mixed  
Calculation:   
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mA/min (sample) - mE/min (blank)  
μM/min = -----------------------------------------------  
11.28  
Referred to haemoglobin content:  
AChE activity (μM/min) * 2$  
μM/min/μmol Hb = --------------------------------------  
μM Hb  
$ Factor for correction of different dilution in the determination of haemoglobin and 
AChE since the whole blood specimen has been diluted with 0.1ml of sample to 2.0ml 
with diluting reagent  
c) Plasma-BChE activity:  
Sample preparation:  
Thawed plasma was centrifuged with high speed for 1-2 min to remove cryoprecipitate.  
Conditions: Wavelength: 436 nm, Extinction coefficient: 11.28 * 103M-1cm-1, 
Temperature: 37°C, Cuvet volume: 3.16 ml, Recording time: 2 min, Cuvets with 1 cm 
light path  
Substrate blank%:  
- 3000 μl phosphate buffer (PP), 100 μl DTNB, 50 μl BuSCh  
- PP, DTNB and ethopropazine were added to cuvet, equilibrated for 10 min(37°C) and 
reaction with BuSCh was started  
Sample:  
- 3000 μl PP, 100 μl DTNB, 10 μl sample(Plasma), 50 μl BuSCh  
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- PP, DTNB, ethopropazine and sample were added to cuvet, equilibrated for 10 
min(37°C) reaction with BuSCh was started .  
Calculation:  
mE/min (sample) - mE/min (blank)  
μM/min = ------------------------------------------------  
11.28  
Referred to plasma content:  
mU/ml plasma= μM/min * dilution factor (=316)  
 
ANNEXURE 5 – STANDARD OPERATING PROTOCOL FOR RBC AChE CHECK 
MOBILE  
 
Components of AChE check mobile  
First step – Entry of Patient details  
- Place RBC check mobile horizontally  
- Avoid direct sun light  
- Switch-on  
 
Second step- Background value of cuvete measurement  
1. Place white capped covets into covet slot  
2. Press „NULL“(„ZERO“)  
3. Remove covet, remove white cap and place covet into parking position  
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Third step- Measurement of haemoglobin  
4. Take blood with 10μl EDTA capillary  
5. Insert capillary into open cuvet  
6. Screw cuvet with white cap and mix carefully until all blood is transferred from the 
Capillary into the cuvet  
7.Place capped cuvet with blood sample into the cuvet slot Cave: Capillary must not be in 
the Optical path  
8. Press „Hb“  
After measuring the back ground value an icon for hemoglobin will be appeared in the 
screen.Venous blood is collected at this point using sterile precautions . Soon after the 
collection of blood in the syringe 10 microlitres of blood will be collected in 2 EDTA 
coated capillaries as well.  
One capillary blood will be used for BuChE and one for AChE measurements.  
Cuvete is now removed from the port, white cap is removed and the capillary for AChE 
Measurement will be added to the cuvete. Following which it is sealed with white cap 
and the blood in the capillaries will be mixed with buffer reagents by shaking 
movements. 
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 All capillary blood has to be mixed with buffer and it’s made sure by visualizing the 
clear capillary. The position of the capillary should be perpendicular to the surface so that 
it doesn’t interfere with the Photometric measurements. .  
Fourth step- Mixing the reagent with the blood  
9.Remove cuvet, replace white cap by red reagent cap  
10.Press „START“ and rotate cuvet overhead simultaneously  
After well mixing cuvete is replaced in the measuring port and the haemoglobin icon is 
pressed. This will show start icon again along with instruction for the next step in 
English.  
Cuvee is removed from the port and a reagent cap which is red coloured for RBC AChE 
and yellow coloured for BuChE is agents. After exchanging the red coloured RBC AChE 
press the start button along with simultaneous mixing of blood with reagent through 
shaking movements. This will ensure that the blood is mixed with the reagent for 10 
seconds  
Fifth step- Enzyme measurement  
11.Rotate cuvet overhead for 10 sec  
12.Place cuvet in cuvet slot, press START  
13.The result will be shown after 70 sec  
At the end of 10 seconds keep the red capped cuvee in the port press the start button so 
that it measured the RBC AChE in 70 seconds. 126  
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Enzyme level is measured by spectrophotometric method.  
This value gets saved automatically and also will be entered in a register for each 
patients.  
Following the RBC AChE measurement go back to the main menu and press the BChE 
icon. The entire process is exactly the same except for the 4 th step where instead of red 
cap we uses yellow cap. According to the manufacturer this machine can be used at a 
wide range of temperature from 10 to 50degree Celsius and the results are normalized to 
37 degree Celsius .Figure below shows various steps in determination of Enzyme 
activity.  
The measurement of enzyme activity in the whole blood is by using the modified Ellman 
method which is different from the original Ellman by the use of BChE Inhibitor 
Ethopropazine, more temperature stability, and use of a different wavelength of 436nm. 
436 nm reduces the background hemoglobin absorption and by using selective BChE 
Inhibitor, Enzymes assays can be done in whole blood and unnecessary centrifugation 
can be avoided. 
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ANNEXURE 6: data sheet  
 
 
 
SL ASCERT AGE SEX COMPID CNAME MID WHO OPTYPE PERC QUANT T1MA TCMC TOUT1 TOUT2 TOUT3 TOUT4 TOUT5 TOUT6 TOXIDR1 TOXIDR2 TOXIDR3 TOXIDR4 TOXIDR5 TOXIDR6 TOXIDR7
1 2 22 1 1 chlorpyrifos 3 2 2 50.00 #NULL! 3.00 14.00 0 0 0 1 0 0 0 0 1 0 1 0 1
2 1 61 1 1 phorate 3 1 2 20.00 250 1.00 1.00 0 0 0 0 0 0 1 0 0 0 1 0 1
3 1 21 1 1 chlorpyrifos 1 2 2 50.00 20 0.50 3.00 0 0 0 0 0 0 1 1 0 0 1 0 0
4 2 19 1 0  #NULL! #NULL! 9 #NULL! #NULL! 0.50 3.00 0 0 0 0 0 0 1 0 0 1 1 0 1
6 1 26 1 1 dichlorvos 3 1 1 83.00 20 0.50 2.50 0 1 1 1 0 0 1 0 0 0 1 0 1
7 2 24 1 0  #NULL! #NULL! 9 #NULL! 100 0.25 1.00 0 1 0 0 0 0 1 1 0 1 1 0 0
8 1 35 1 1 carbofuran 3 2 3 25.00 50 1.00 5.00 0 0 1 0 0 0 0 0 0 0 1 0 0
9 2 18 1 1 phorate 1 1 2 #NULL! #NULL! 0.50 2.50 0 0 1 0 0 0 1 1 1 1 1 0 1
11 1 28 1 1 phorate 3 1 2 10.00 150 0.50 2.00 0 0 1 0 0 0 1 1 0 0 1 0 1
12 1 19 1 1 monochrotophos 3 1 1 36.00 50 0.50 5.00 0 0 1 0 0 0 1 0 1 1 1 0 0
13 1 38 1 1 prophenofos 3 2 2 50.00 25 1.00 5.00 0 0 1 1 0 0 1 1 0 0 1 0 0
14 1 28 1 1 dimethoate 3 2 1 30.00 100 1.00 3.00 0 1 1 1 1 0 0 0 0 0 0 0 0
16 1 30 1 1 monochrotophos 3 1 1 30.00 50 1.50 2.30 0 0 1 1 0 0 1 1 1 1 0 0 1
17 1 18 1 1 phenthoate 3 2 1 50.00 10 0.50 23.50 0 1 1 1 1 0 0 0 0 0 0 0 0
18 1 28 1 1 carbofuran 3 1 3 3.00 50 1.00 7.75 0 1 1 1 0 0 0 0 1 0 0 0 0
21 2 46 1 1 dichlorvos 3 1 1 76.00 5 0.25 1.25 0 0 1 0 0 1 0 0 0 0 1 0 1
22 1 21 1 1 monochrotophos 3 1 1 36.00 100 0.50 7.00 0 0 1 0 0 0 1 0 1 0 1 0 1
23 1 18 1 0  #NULL! #NULL! #NULL! #NULL! 50 1.00 4.00 0 1 0 1 0 0 1 0 0 1 1 0 1
25 1 60 1 1 chlopyrifos, cypermethrin 3 2 2 50.00 50 1.00 20.00 0 1 1 1 1 0 1 0 1 1 1 0 0
27 1 70 1 1 profenofos 3 2 2 85.00 100 0.50 2.00 0 1 0 1 0 0 1 0 0 1 1 0 1
28 1 74 1 1 triazophos, cypermethrin 3 1 2 35.00 100 1.00 1.00 0 0 0 0 0 0 1 0 1 1 1 0 0
30 1 26 1 1 quinalophos 3 2 2 25.00 100 4.00 6.50 0 0 1 1 0 0 0 0 1 1 1 0 0
33 2 28 1 0  #NULL! #NULL! 9 #NULL! #NULL! 0.50 3.00 0 0 1 0 0 0 0 0 0 0 1 0 0
34 1 21 1 1 monochrotophos 2 1 1 10.00 300 1.00 23.00 0 0 1 1 0 1 1 0 0 1 1 0 1
35 1 24 1 1 phorate 1 1 2 10.00 5 0.50 2.00 0 0 1 0 0 0 0 0 0 0 0 0 0
36 1 20 1 1 chlorpyrifos 3 2 2 20.00 80 0.50 4.00 0 1 0 0 0 0 0 0 0 1 1 0 1
38 1 28 1 1 quinalophos 3 2 2 25.00 50 1.00 3.00 0 0 1 1 0 0 0 0 0 1 1 0 0
40 1 29 1 1 prophenophos, cypermethrin 3 2 2 40.00 200 0.50 0.50 0 1 1 1 0 0 1 1 0 0 1 0 0
42 1 25 1 1 profenophos 3 2 2 40.00 50 0.50 3.66 0 0 1 1 0 0 1 0 1 1 1 0 0
43 1 21 1 1 monochrotophos 2 1 1 36.00 25 1.00 4.75 0 0 1 1 1 1 0 0 0 1 0 0 0
44 1 26 1 1 chlorpyrifos 2 2 2 20.00 50 0.50 2.00 0 0 1 0 0 0 0 0 0 0 1 0 0
46 2 46 1 1 chlorpyrifos, cypermethrin 3 2 2 50.00 #NULL! 1.00 3.50 0 0 1 0 0 0 0 0 0 0 1 0 1
48 1 40 1 1 phenthoate 3 2 1 50.00 #NULL! 1.00 7.00 0 0 1 1 0 1 0 0 0 0 0 0 0
49 2 18 1 0  #NULL! #NULL! 9 #NULL! #NULL! 4.00 4.00 0 0 0 0 0 0 1 0 1 1 1 0 1
50 1 36 1 1 dimethoate, alprazolam 3 2 1 30.00 100 4.00 4.00 0 0 0 0 0 0 0 0 0 0 1 0 1
51 2 65 1 0  #NULL! #NULL! 9 #NULL! #NULL! 0.50 10.00 0 0 1 1 0 0 0 0 0 0 1 0 1
52 1 28 1 1 carbofuran 3 1 3 3.00 100 1.00 4.00 0 0 1 1 0 0 1 0 0 1 0 0 0
53 1 55 1 1 monochrotophos 3 1 1 36.00 100 1.00 4.75 0 0 1 1 0 0 1 0 1 1 1 0 1
54 2 26 1 1 monochrotophos 2 1 1 36.00 250 0.50 2.00 0 0 0 1 0 0 1 0 0 0 1 0 1
56 2 24 1 0  #NULL! #NULL! #NULL! #NULL! 50 0.25 6.00 0 0 1 0 0 0 1 1 0 0 1 0 1
57 2 35 1 1 profenofos 3 2 2 40.00 50 0.50 3.00 0 0 1 1 0 0 0 0 0 0 1 0 1
59 2 51 1 0  #NULL! #NULL! #NULL! #NULL! 50 0.50 4.00 0 0 1 1 0 0 1 0 1 0 1 0 0
60 2 28 1 0  #NULL! #NULL! #NULL! #NULL! 5 0.50 2.00 0 0 1 1 1 0 0 0 0 0 0 0 0
5 1 20 2 1 monochrotophos 3 1 1 10.00 5 1.50 8.00 0 0 0 1 0 0 1 0 1 0 1 0 0
10 1 18 2 1 phospamidon 3 1 1 40.00 #NULL! 1.00 12.00 0 0 1 1 0 0 0 0 0 1 1 0 1
15 1 19 2 1 chlorpyrifos, cypermethrin 3 2 2 50.00 100 4.00 7.50 0 0 1 1 0 0 1 0 0 1 1 0 0
19 1 41 2 1 chlorpyrifos 3 2 2 1.50 500 1.00 6.00 0 1 1 1 0 0 1 0 1 0 1 0 0
20 1 29 2 1 acephate, imadacloprid 3 2 1 50.00 50 0.50 6.00 0 0 1 1 1 0 0 0 0 1 1 0 0
24 1 35 2 1 phorate 3 1 2 10.00 50 0.50 5.50 0 0 1 1 0 0 0 0 0 1 1 0 0
26 1 21 2 1 monochrotophos 3 1 1 36.00 20 0.50 1.25 0 0 1 1 0 0 1 0 1 0 1 0 0
29 1 20 2 1 malathion 3 3 1 5.00 5 0.50 1.00 0 0 0 0 0 0 0 0 0 0 1 0 0
31 1 30 2 1 phorate 3 1 2 10.00 5 0.50 3.00 0 1 0 0 0 0 0 0 0 0 1 0 0
32 1 28 2 1 profenofos 3 2 2 30.00 50 1.00 4.00 0 0 1 1 0 0 1 0 1 0 1 0 0
37 1 27 2 1 monochrotophos 3 1 1 36.00 5 0.50 6.00 0 0 1 0 0 0 0 0 1 0 1 0 0
39 2 18 2 0  #NULL! #NULL! 9 #NULL! 50 4.00 10.00 0 0 1 1 0 0 1 0 1 1 1 0 1
41 1 30 2 1 phorate 2 1 2 90.00 25 0.50 2.00 0 0 1 1 0 0 0 0 0 0 1 0 0
45 2 29 2 0  #NULL! #NULL! 9 #NULL! #NULL! #NULL! #NULL! 0 0 0 0 0 0 0 0 1 1 0 0 1
47 1 33 2 1 phorate 3 1 2 10.00 20 1.00 6.00 0 0 1 1 0 0 0 0 0 1 1 0 0
55 1 18 2 1 carbofuran 1 1 3 3.00 50 0.50 3.00 0 0 0 0 0 0 0 0 0 0 0 0 0
58 1 18 2 1 chlorpyrifos, permethrin 3 2 2 50.00 20 0.50 3.50 0 0 1 1 0 0 1 1 0 0 1 0 0
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TOXIDR7 TOXIDR8 TOXIDR9 POP POPSCORE GCS PUPIL PULSE SYSBP DIABP RESP SATUR GRBS DIAP CREPTS SAL FROATH FASICUL SBC PARA ABDTEN FEVER PSCHOLI RBCCHOL INTERMED DURINTER
1 0 0 1 3 15 1 140 110 80 26 98 125 0 0 0 0 1 4 1 0 0 60 6.0 1 #NULL!
1 0 1 2 5 12 1 100 200 100 46 80 280 1 1 1 1 0 #NULL! 1 0 0 96 0.5 1 #NULL!
0 0 0 1 1 15 2 82 110 70 20 98 87 0 0 1 0 1 16 0 0 0 10,718 37.0 0 #NULL!
1 0 0 1 2 15 1 108 140 100 16 98 96 1 1 1 1 1 10 1 0 0 117 0.0 0 #NULL!
1 0 1 2 4 3 3 130 110 60 30 60 115 1 1 1 1 0 #NULL! 1 0 0 308 18.8 0 #NULL!
0 0 0 1 3 15 1 116 100 60 20 98 234 1 0 1 0 0 #NULL! 0 1 0 253 0.6 1 0
0 0 0 1 0 15 2 104 110 70 16 96 110 0 0 0 0 0 #NULL! 0 0 0 5,217 18.8 0 #NULL!
1 0 1 2 5 3 1 150 100 60 30 #NULL! 183 1 1 1 1 1 #NULL! 1 0 0 93 0.0 0 #NULL!
1 0 1 2 6 8 1 112 120 70 32 92 156 1 1 1 1 0 #NULL! 0 0 0 437 1.8 0 #NULL!
0 0 0 1 3 15 1 108 140 80 24 96 180 0 0 1 0 1 30 0 0 0 118 2.0 1 5
0 0 0 1 3 15 1 76 100 60 20 98 91 0 1 0 0 0 20 0 0 0 5,945 41.4 0 #NULL!
0 0 0 1 1 15 2 110 120 70 20 98 110 0 0 0 0 0 30 0 0 0 1,125 8.0 0 #NULL!
1 0 1 2 6 3 1 150 140 80 20 #NULL! #NULL! 1 1 1 1 0 #NULL! 1 0 0 77 0.0 1 13
0 0 1 1 1 13 3 140 96 64 24 96 88 0 0 0 0 0 #NULL! 0 0 1 5,781 35.9 0 #NULL!
0 0 1 1 2 14 2 120 120 80 20 98 120 0 0 0 0 0 34 0 0 0 4,544 41.4 0 #NULL!
1 0 1 1 3 10 1 82 100 70 16 98 #NULL! 0 1 0 0 0 #NULL! 0 0 0 210 8.9 1 5
1 1 1 2 7 5 1 68 100 60 26 100 95 0 1 1 1 1 #NULL! 0 0 0 153 1.4 1 13
1 0 1 2 6 #NULL! 1 120 120 70 32 94 112 1 1 1 1 0 #NULL! 1 0 0 105 0.0 0 #NULL!
0 0 1 2 4 12 1 90 110 70 16 99 130 1 0 1 1 0 #NULL! 0 0 1 63 6.3 1 8
1 1 1 2 6 3 2 175 180 100 40 70 106 0 1 1 1 1 #NULL! 1 0 0 102 0.8 1 12
0 0 1 2 6 6 1 64 130 80 40 78 124 1 1 1 1 0 #NULL! 1 0 0 164 1.1 1 10
0 0 0 1 1 15 2 130 110 60 22 96 150 0 0 0 0 0 20 0 0 0 71 4.1 0 #NULL!
0 0 0 1 1 15 2 84 110 70 22 98 116 0 0 0 0 0 25 0 0 0 170 1.3 1 4
1 0 1 2 6 3 1 87 120 80 20 60 111 0 1 0 0 0 #NULL! 1 0 0 94 0.0 0 #NULL!
0 0 0 1 1 15 2 90 120 70 18 98 106 0 0 0 0 0 24 0 0 0 7,471 46.0 0 #NULL!
1 0 0 1 3 15 1 112 120 70 32 97 112 1 0 1 0 0 20 0 0 0 133 6.6 0 #NULL!
0 0 1 1 2 15 2 108 94 60 20 98 104 0 0 0 0 0 20 0 0 0 146 12.9 0 #NULL!
0 0 0 1 2 15 3 146 130 70 26 94 151 0 0 0 0 0 20 0 0 0 90 7.5 0 #NULL!
0 0 0 1 1 15 2 94 100 60 24 94 163 0 1 1 0 0 18 0 0 0 160 0.0 0 #NULL!
0 0 1 2 6 7 1 112 110 70 20 83 122 0 0 1 0 0 #NULL! 0 0 0 62 0.4 1 5
0 0 0 1 1 15 2 114 110 80 20 100 94 0 0 0 0 0 26 0 0 0 119 16.8 0 #NULL!
1 0 1 2 6 7 1 126 120 70 32 86 288 1 1 0 0 0 #NULL! 0 0 0 448 10.0 1 8
0 0 1 2 5 7 1 84 0 0 20 100 205 0 0 0 0 0 #NULL! 0 0 0 170 2.4 0 #NULL!
1 1 1 3 8 3 1 120 140 80 30 78 106 0 1 1 1 1 #NULL! 0 0 0 15,853 3.5 0 #NULL!
1 1 1 2 7 8 1 64 100 60 22 97 98 0 1 0 0 1 #NULL! 0 0 9 9,933 1.6 0 #NULL!
1 0 1 2 4 3 2 90 140 80 8 89 72 0 1 0 0 0 #NULL! 0 0 0 3,664 34.8 0 #NULL!
0 0 0 1 1 15 2 80 110 60 22 94 150 1 0 0 0 1 20 0 0 0 1,681 2.7 0 #NULL!
1 0 1 2 4 15 1 84 120 70 42 89 236 1 1 0 0 0 #NULL! 1 0 0 137 1.9 1 13
1 0 1 2 4 3 1 150 100 70 10 85 223 1 0 1 1 0 #NULL! 0 0 0 210 2.8 0 #NULL!
1 0 0 2 5 14 1 104 110 70 22 57 138 1 1 1 0 0 22 0 0 0 76 1.5 0 #NULL!
1 0 0 1 2 15 2 126 120 70 30 86 119 1 1 0 0 0 5 1 0 0 59 1.6 0 #NULL!
0 0 0 1 1 15 2 88 130 80 16 99 116 0 0 0 0 0 15 0 0 0 535 0.2 0 #NULL!
0 0 0 1 1 15 2 84 130 70 17 98 125 1 0 0 0 1 24 0 1 0 404 4.1 0 #NULL!
0 0 1 3 8 3 1 25 0 0 0 #NULL! #NULL! 0 1 1 0 0 #NULL! #NULL! 0 0 66 2.0 0 #NULL!
1 0 0 2 4 15 1 130 120 90 30 98 243 0 0 1 1 0 5 1 0 0 32 1.3 0 #NULL!
0 0 0 1 3 14 2 156 110 80 34 94 94 1 0 1 1 0 #NULL! 0 1 0 369 24.0 1 9
0 0 0 1 1 15 2 80 110 70 20 94 205 0 0 0 0 0 26 0 0 0 966 43.0 0 #NULL!
0 0 1 1 1 15 2 84 110 70 22 98 155 0 0 0 0 0 #NULL! 0 0 0 2,013 1.7 0 #NULL!
0 0 0 1 3 15 #NULL! 118 110 70 20 98 127 0 0 0 0 1 5 1 0 0 86 5.2 1 8
0 1 1 1 3 14 2 92 120 70 24 98 101 1 0 1 1 0 10 0 0 0 148 0.5 0 #NULL!
0 0 0 1 1 15 2 84 110 80 20 98 86 0 0 0 0 0 32 0 0 0 5,564 40.0 0 #NULL!
0 0 0 1 1 15 2 110 120 70 18 97 126 #NULL! 0 0 0 0 24 0 0 0 5,958 41.0 0 #NULL!
0 0 1 2 4 4 2 122 100 70 12 100 79 0 1 1 1 1 #NULL! 1 0 0 175 30.2 1 11
0 0 0 1 1 15 2 98 100 60 28 96 94 0 0 0 0 0 26 0 0 0 1,832 40.3 0 #NULL!
1 0 0 2 4 15 1 122 90 50 42 62 169 1 1 0 0 0 20 0 1 0 3,672 4.0 0 #NULL!
0 0 0 1 1 15 3 84 120 80 22 99 119 0 0 0 0 0 32 0 0 0 10,754 32.0 0 #NULL!
1 1 1 3 9 5 1 54 90 60 24 60 438 0 1 0 0 0 #NULL! 1 0 0 233 1.0 1 9
0 0 0 1 1 15 2 78 110 80 20 96 120 0 0 0 0 0 22 0 0 0 #NULL! #NULL! 0 #NULL!
0 0 0 1 1 15 1 84 110 80 22 98 97 0 0 0 0 0 40 0 0 0 5,000 40.2 0 #NULL!
0 0 0 1 2 14 2 106 110 60 24 99 117 0 0 0 0 0 30 0 0 0 81 17.7 0 #NULL!
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ICUADMI TOTADMI VENT VENTDUR VENTIND TRACHEO CARARRES RESARRES INFECTIO LRT UTI CRBSI THROMB SINUSITI ORGCUL LAVCMC CHARCMC ATROPIIN ATROPDUR ATROPTOT DEATH DEATHCAU
1 23 1 17 impend resp fail 1 0 0 1 1 0 0 0 0 NFGNB 0 0 0 5 109 0  
1 1 1 #NULL! low sensorium 1 0 0 1 1 1 0 0 0 pseudomonas 1 1 16 5 545 0  
0 3 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 0 1 10 0  
1 16 1 4 airway protection, respiratory failure 0 0 0 1 1 0 0 0 0  1 0 64 3 304 0  
1 8 1 4 low sensorium 0 0 0 1 1 0 0 0 0 gram negative bacilli 0 0 90 2 96 0  
0 4 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 60 3 236 0  
0 4 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 0 1 5 0  
1 21 1 10 low sensorium 0 0 0 1 1 0 0 0 0 NFGNB- sputum , blood C/s - klebsiella ESBL 0 0 31 3 107 0  
1 4 1 2 low sensorium 0 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 64 2 280 0  
1 17 1 12 respiratory failure 1 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 62 3 359 0  
1 4 1 2 low sensorium 0 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 30 2 62 0  
0 5 0 #NULL!  #NULL! 0 0 1 1 0 0 0 0 nil 0 0 10 2 52 0  
1 24 1 18 low sensorium , respiratory failure 1 0 0 1 1 0 0 0 0 nil 0 0 124 4 589 0  
0 4 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 0 0 0 0  
0 4 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 0 2 72 0  
1 14 1 10 low sensorium 0 0 0 1 1 0 0 0 0 staphlococcus, pseudomonas klebsiella- sputum 0 0 0 6 213 0  
1 13 1 18 low sensorium 1 0 0 1 1 0 0 0 0 klesiella, pseudomonas, stpahylococcus aureus- sputum, Aceinobacter -Bld culture 0 0 82 3 1,096 0  
0 1 1 #NULL! respiratory failure 0 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 64 #NULL! #NULL! 0  
1 15 1 8 respiratory failure - intermediate syndrome 1 1 1 1 1 0 0 0 0 aceinobacter on sputum 0 0 7 9 491 0  
1 13 1 13 low sensorium , pulmonary edema 1 0 0 1 1 0 0 0 0 NFGNB, pseudomonas -resistant to meropenem 0 0 0 5 509 0  
1 19 1 16 respiratory failure, low sensorium 1 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL! NFGNB 1 1 14 6 186 0  
0 4 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 4 2 59 0  
1 8 1 4 respiratory failure- IMS 0 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 64 4 474 0  
0 3 1 3 low sensorium, respiratory failure 0 1 1 1 1 0 0 0 0 staphylococcus aureus- blood 0 0 9 2 108 1 infection- pneu
0 1 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 0 0 0 0  
0 5 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 32 3 270 0  
0 3 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 0 2 60 0  
0 4 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 0 0 0 0  
0 3 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 12 2 146 0  
1 10 1 6 low sensorium 0 0 0 1 1 0 0 0 0 pseudomonas- sputum 0 0 100 5 380 0  
0 6 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 0 3 24 0  
1 #NULL! 1 15 low sensorium, respiratory failure-IMS 1 0 0 1 1 0 0 0 0 klesiella- blood 0 0 0 3 24 0  
1 6 1 6 low sensorium 0 0 0 1 1 0 0 0 0 NFGNB and MRSA - blood and sputum 0 0 136 2 530 1 infection- pneumonia and sepsis
1 1 1 #NULL! low sensorium, respiratory failure 0 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 134 #NULL! 134 0  
1 6 1 2 low sensorium 0 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  1 1 12 2 15 0  
1 9 1 4 low sensorium, respiratory failure 0 0 0 1 1 0 0 0 0  0 0 0 2 95 0  
0 5 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 0 2 32 0  
1 26 1 18 repiratory failure-IMS 1 0 0 1 1 0 0 0 0 pseudomonas, klebsiella- sputum 0 0 256 2 785 0  
1 14 1 7 low sensorium 0 0 0 1 1 0 0 0 0 NFGNB-sputum 1 1 64 3 310 0  
1 6 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 32 3 168 0  
1 8 1 3 respiratory failure 0 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 32 2 180 0  
1 8 1 2 respiratory failure 0 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 64 2 320 0  
0 3 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 32 2 96 0  
1 5 1 5 low sensorium, arrest at admission 0 1 1 1 1 0 0 0 0 nil 0 0 60 2 466 1 cholinergic cri
1 10 1 3 low sensorium 0 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 32 2 88 0  
1 16 1 9 respiratory failure 1 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 1 1 193 0  
0 9 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 0 2 32 0  
0 7 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 10 5 276 0  
1 14 1 10 respiratory failure 1 0 0 1 0 0 0 1 0 nil 0 0 30 5 426 0  
1 6 0 #NULL!  #NULL! 0 0 1 1 0 0 0 0 0 1 0 9 4 498 0  
0 1 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 0 0 0 0  
0 1 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 0 0 0 0  
1 20 1 15 low sensorium and respiratory failure - IMS 1 0 0 1 1 0 0 0 0 klebsiella - sputum CRO 0 0 0 5 176 0  
0 3 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 0 2 32 0  
0 #NULL! 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 10 2 27 0  
0 4 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 0 1 25 0  
1 24 1 14 low sensorium, repiratory failure 1 0 0 1 0 1 0 0 0 klebsiella- urine 0 0 222 3 958 0  
0 5 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 8 3 116 0  
0 3 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 0 1 28 0  
0 4 0 #NULL!  #NULL! 0 0 0 #NULL! #NULL! #NULL! #NULL! #NULL!  0 0 0 2 72 0  
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